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nothing is more fatal to the progress of the human mind than to presume that our views 
of science are ultimate, that our triumphs are complete, that there are no mysteries in 
nature, and that there are no new worlds to conquer 
  
Humphry Davy 
ABSTRACT 
Following viral infection or vaccination dendritic cells (DC) perform an intricate series 
of roles at the interface of innate and adaptive immunity. Peripheral DC recognition of 
pathogen associated molecular patterns initiates signaling cascades leading to 
morphological and phenotypic maturation. The differentiation to a mature phenotype 
licenses DCs to efficiently prime T- and B-lymphocytes. Thus, DCs shape early innate 
immune responses that limit viral replication and initiate the generation of protective 
and adaptive immunological memory. 
 
In this thesis, we began by studying the interaction of human primary DCs with human 
adenovirus (AdV). While the causative agent of a variety of human diseases, AdVs are 
also a valuable research tool for probing virological, immunological, and cellular 
mechanisms of nature. Recombinant human AdVs (rAdV), rendered replication 
incompetent and thus unable to cause disease, have gained prominence as gene delivery 
vehicles in multiple vaccine trials. In light of the clinical importance of AdV vectors, 
we employed a reductionist approach to study mechanisms of virus-mediated 
regulation of human DC function. Since DCs activate adaptive immunity, we extended 
our investigations to the impact of rAdV on the activation of T-lymphocytes. These 
studies are particularly relevant since the induction of potent T-cell responses is one 
objective of rAdV based vaccine vectors. 
 
In assessing the interaction of rAdV with primary human blood myeloid and 
plasmacytoid DC subsets, we found that activation of these cells was dependent on 
rAdV type. rAdV-35 more efficiently infected DCs than rAdV-5, and matured blood 
DCs and strongly induced interferon-α in plasmacytoid DCs. Infection by rAdV-35 
was dependent on the receptor CD46, whereas the receptor for rAdV-5 was less clear. 
We then showed that lactoferrin facilitated rAdV-5 infection of multiple DC subsets in 
a similar manner to epithelial cells. rAdV-exposed DCs were able to process and 
present rAdV encoded transgenes and activate polyfunctional memory T cells, which 
indicated that rAdV infected DCs retained their antigen presentation capacity. 
However, it remained unclear from these studies whether rAdV affected the activation 
of naive T cells, which is an important step for vaccination. To this end, rAdV-35 was 
found to strongly inhibit activation of naive CD4+ T cells through binding of its 
cellular attachment receptor, CD46. Attenuated activation was characterized by lower 
proliferation and IL-2 production, as well as deficient NF-κB nuclear translocation. 
Further studies showed that cross-linking with CD46 monoclonal antibodies and 
recombinant trimeric rAdV-35 knob proteins was sufficient to cause similar 
suppression as the whole virus, substantiating the role of CD46 in regulating CD4+ T-
cell function.  
 
Our findings provide insights into the mechanisms by which host immune cells respond 
to rAdV and also how the virus may act to modulate host cell function. These findings 
may also guide the development of rAdVs as vaccine vectors. 
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PREFACE 
This thesis has been divided into two main sections. In the first I will introduce basic 
concepts of viral immunity with particular focus on our current knowledge in humans. 
It is my intention that this introduction will be accessible to readers whom are outside 
this specific field. The historical rationale for using adenoviruses as tools in research 
and as vaccine vectors will be discussed in order to provide a greater contextual 
significance to the work in this thesis. The aims of the thesis will then be presented. 
Finally, a broad overview of the origin, definition, phenotype, and function of dendritic 
cells and T cells will be presented followed by basic adenovirus virology and vector 
generation. 
 
In the second section I will cover the materials and methods used throughout the papers 
in the thesis. Then, the results from papers I-IV will be presented and discussed 
together in order to demonstrate how the findings are related. Studies performed here 
used a reductionist approach that we hope provides instruction for understanding 
human immune cell function and guidance for using recombinant adenoviruses as 
vaccine vectors in humans. The thesis will conclude with remarks on these topics and 
on future directions, followed by reprints of the original papers. 
 
 
William C. Adams                                           May 16th, 2011 
ABBREVIATIONS 
AA amino acids 
Ab antibody 
AdV human adenovirus 
BDCA blood dendritic cell antigen 
CAR coxsackievirus-adenovirus receptor 
CCR c-c chemokine receptor 
CD cluster of differentiation 
CMV cytomegalovirus 
CTL cytotoxic T-lymphocyte 
CTLA-4 cytotoxic T-lymphocyte antigen-4 
cyt cytoplasmic tail (as in CD46) 
DAMP danger associated molecular pattern 
DC dendritic cell 
dDC interstitial dermal dendritic cell 
DC-SIGN DC-specific intercellular adhesion molecule-3-grabbing non-integrin 
DNA deoxyribonucleic acid 
ds double stranded (as in DNA) 
ELISA enzyme linked immunosorbent assay 
GFP green fluorescence protein 
GM-CSF granulocyte macrophage-colony stimulating factor 
HHV-6 human herpes virus-6 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
IFN interferon 
Ig immunoglobulin 
IκBα nuclear factor of κ light polypeptide gene enhancer in B-cells 
inhibitor, α 
IL interleukin 
ip infectious virus particle 
IRF interferon regulatory factor 
ITAM immunoreceptor tyrosine-based activation motif 
LC Langerhans cell 
Lf lactoferrin 
LPS lipopolysaccharide 
TLR toll like receptor 
mAb monoclonal antibody 
mDC myeloid dendritic cell 
MDDC monocyte derived dendritic cell 
mip macrophage inflammatory protein 
MV measles virus 
NF-κB nuclear factor κ-light-chain enhancer of activated B cells 
NHP non-human-primate 
NK cell natural killer cell 
OL overlapping (as in peptide) 
PAMP pathogen associated molecular patterns 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
PD programmed death 
pDC plasmacytoid dendritic cell 
PRR pathogen recognition receptor 
rAdV replication incompetent recombinant adenovirus 
RNA ribonucleic acid 
RPMI Roswell Park Memorial Institute medium 
RLR retinoic acid inducible–gene I (RIG-I)-like receptor 
RT-PCR real-time polymerase chain reaction 
SCR short consensus repeat of CD46 
ss single stranded (as in RNA) 
TCR T-cell receptor 
Tf transferrin 
Th helper T-cell 
TNF tumor necrosis factor 
VA-RNA virus associated ribonucleic acids 
vp virus particle 
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1 INTRODUCTION 
1.1 HUMAN IMMUNOLOGY AND VACCINATION 
Organisms face continuous challenge throughout most anatomical sites from self-
antigen, cancers, commensal bacteria, latent viruses, and external pathogens. Survival 
depends on finely balancing the generation of tolerance to self-antigen and commensal 
flora and the generation of protective immunity to acute and chronic pathogen 
infections. Vertebrates of the kingdom Animalia, such as ourselves, have evolved a 
complex three-limbed, interconnected immunological system, which in general terms 
includes: complement, and innate and adaptive immunity. These three limbs together 
have a remarkable capacity to confront immense pathogen diversity in nature. 
Commensal bacteria (1) and chronic or latent viruses (2) also play many well defined 
and as yet undefined roles in regulating tolerance and immunity. The evolutionarily 
ancient complement system serves as a primary host defense that eliminates microbial 
invaders by a “hub-like network” of canonical and alternative pathways (3). 
Amplification of these pathways from the normal steady-state sampling leads to the 
formation of lytic pores, termed terminal complement complex, on marked host or 
microbial cells that causes their destruction. The numerous cell types of the more 
recently evolved second limb, the innate immune system, recognize pathogen 
expressed chemical signatures by germ line-encoded receptors and work in concert 
with complement to provide rapid and immediate responses and clearance of antigen 
(4). Cells of the innate immune system, namely dendritic cells (DC), orchestrate direct 
antimicrobial responses by type-1 interferons (IFN-I) and tolerance when appropriate. 
Perhaps most significantly the innate system in concert with complement initiate and 
regulate adaptive immune responses, which can provide long-lasting immunological 
memory with humoral antibody (Ab) (B-cell) and cellular (T-cell) responses. T cells 
function by either directly killing infected cells or by supporting B cells that can 
produce antibodies that neutralize extracellular pathogens. However, a potential cost of 
adaptive immunity is developing autoimmune disease or allergy. The three limbs of 
immunity, which are coevolving with each other and with commensal and external 
microbes, are thus linked by a complex web of interactions that together enables an 
organism to protect against pathogens while limiting damage to self.  
 
In 1796 Edward Jenner found that inoculation with cowpox virus protected individuals 
against subsequent human smallpox infection. Vaccines are now known to exploit 
adaptive immunological memory in order to provide individual and herd protection 
against subsequent pathogen challenge (5-7). Administration of live attenuated virus, 
killed virus, or virus-like-particles (VLP) that do not cause disease can prime the 
immune system and generate protective cellular and humoral memory. While the 
correlate of protection for most approved vaccines is Ab titers (humoral immunity), the 
induction of cellular T-cell responses is nonetheless important. Vaccination exemplifies 
the adaptability and specificity of the host immune response. The live-attenuated 
yellow fever virus 17D (YFV) vaccine potently primes the adaptive immune system 
and provides durable protection of the host upon wild-type YFV challenge (8). Yet, the 
traditional empiric vaccine approach used to make vaccines like that against YFV is 
largely inadequate for developing vaccines against pathogens such as HIV-1 (the 
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causative agent of AIDS), Plasmodium falciparum (causing Malaria), and 
Mycobacterium tuberculosis (TB) for which there are no efficacious vaccines (9). Thus, 
there is a strong need to develop novel strategies to generate vaccine induced immunity.  
 
1.2 ADENOVIRUSES IN BASIC AND CLINICAL RESEARCH 
Viruses are a remarkably diverse Order of ancient obligate intracellular pathogens that 
cause a variety of human diseases. They are classified as obligate because their 
existence depends on a host cell. Human adenoviruses (proper nomenclature is HAdV; 
AdV is used here) of the family Adenoviridae and genus Mastadenovirus refers to at 
least 50 types subdivided into 6 distinct species that share similar capsid structures and 
genome organization. They cause numerous respiratory, ocular, and gastrointestinal 
diseases in humans. However, AdVs have also been widely used in research to uncover 
biochemical and cellular mechanisms of Nature. Perhaps most noteworthy is the 
discovery of alternative splicing of AdV derived RNA transcripts in infected cells by 
two independent groups (10, 11). These groups observed that viral RNA was not as 
expected transcribed in a collinear manner with its genomic template (genes). In early 
gene therapy trials employing replication incompetent recombinant adenoviruses 
(rAdV) strong immune responses (humoral and cellular) were generated towards 
genomic backbone encoded transgenes (12, 13). These experiments suggested that 
rAdVs may be effective vehicles (i.e. vectors) to efficiently deliver and induce 
immunity to encoded pathogen genes. At the present time, rAdV vectors continue to be 
the most widely used viral vectors in pre-clinical and clinical gene therapy (14, 15) and 
vaccine trials for a wide range of human pathogens (16, 17). However, a greater 
understanding of AdVs in the context of basic human immunology is essential for 
providing insights into natural host-pathogen interactions and for potentially enhancing 
their efficacy as vaccine vectors. 
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2 AIMS OF THESIS 
The overall aim of this thesis was to study the interactions of human DCs and T cells 
with human rAdV vectors. We focused on species C AdV-5 and species B AdV-35. 
These particular AdVs were studied because they are used as viral vectors in numerous 
clinical vaccine trials for diseases associated with HIV-1, Plasmodium falciparum, and 
Mycobacterium tuberculosis. The aims were as follows: 
 
• To study the capacity of rAdV-5 and rAdV-35 to infect primary human myeloid 
and plasmacytoid DCs from blood, and induce phenotypic maturation and 
cytokine production in these cells.  
 
• To study receptor usage of rAdV-5 and rAdV-35 on primary human DCs. 
 
• To study the ability of rAdV exposed human DCs to process and present rAdV-
encoded antigen and activate autologous antigen-specific memory T cells. 
 
• To evaluate effects of rAdV vectors on the activation of naive CD4+ T cells. 
 
• To study mechanisms of how rAdV-35 may regulate T-cell function via binding 
to its receptor CD46. 
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3 DENDRITIC CELLS 
3.1 DEFINITION AND GENERAL FUNCTION 
The term dendritic cell (DC) was first used to describe populations of non-adherent 
cells morphologically distinct from macrophages in murine spleens and lymph nodes 
(18, 19). From the Greek word déndron meaning tree, dendritic describes a branched 
morphology of membrane processes extending outward from the cell. The discovery of 
DCs provided the first clues to how lymphocytes were activated with antigen, which 
had been a significant unanswered question in immunology (20-22). These DCs turned 
out to be remarkably similar to the cells Paul Langerhans observed over a century 
before.  
 
The identification of DCs has led to a vast number of studies that have begun to reveal 
the roles of these cells in the immune system. During the steady state DCs are mainly 
circulating in the periphery with an immature phenotype and high endocytic capacity 
that allow them to internalize antigen. A diverse array of cytosolic and endosomally 
expressed pathogen recognition receptors (PRR) also enables DCs to recognize and 
respond to specific and normally conserved viral nucleic acid signatures of extracellular 
and intracellular pathogens. PRR engagement can then initiate downstream signaling 
cascades that lead to DC activation, which is characterized by upregulation of spleen or 
secondary lymphoid organ homing receptors (e.g. CCR7), phenotypic maturation and 
production of cytokines such as IFN-I (23). Together, these events license and support 
DCs to activate antigen-naive T cells. DCs normally migrate from the periphery and 
activate T cells in secondary lymphoid organs. However, skin DCs may also transport 
HSV-1 antigens from the periphery to lymph node resident DCs, which in turn can 
activate CD8+ T cells (24). The morphological and phenotypic changes of matured 
DCs allow them to activate lymphocytes in an antigen specific manner that may be up 
to one-hundred times stronger than other leukocytes (25). To activate T cells, DCs load 
processed peptides on major histocompatibility complex (MHC) (in humans termed 
human leukocyte antigen (HLA)) that bind cognate αβ-T-cell receptors (TCR) 
expressed on T cells. TCR and co-stimulatory signals provided by mature DCs lead to 
activation of cytotoxic CD8+ T cells (cytotoxic T lymphocyte or CTL) and helper 
CD4+ T cells (Th). Although DCs induce T cells to proliferate, DCs themselves do not 
appear to proliferate. While most non-hematopoietic and hematopoietic cells present 
endogenous antigen on MHC-I, DCs are termed professional antigen presenting cells 
(pAPCs) because they can also present exogenous foreign peptides on MHC-II. It has 
been proposed that MHC-II presentation in mature DCs occurs efficiently because 
peptide bound MHC (pMHC)-II are efficiently transported in polarized endosomes 
towards the immune synapse where TCR binding occurs (26, 27). 
 
Attenuation of allograft rejection in mice treated with anti-DC mAbs provided evidence 
that DCs could activate T cells (28) and it is still commonly accepted that DCs are 
crucial in mediating viral immunity (29). However, only recently have studies – where 
specific DC subsets were depleted in mice before pathogen challenge – provided more 
definitive evidence for the role of DCs in controlling infection. Diphtheria toxin 
receptor (DTR) mediated depletion of CD11c+ cells demonstrated that DCs were 
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essential for priming T-cell responses against Listeria monocytogenes (30). Specific 
DTR ablation of BDCA-2 expressing plasmacytoid DCs (pDC) led to attenuated IFN-I 
and increased viral loads after challenge with a DNA murine cytomegalovirus 
(MCMV) (31). Early replication of the RNA Vesicular stomatitis virus (VSV), which 
like MCMV activates pDCs, was also increased when pDCs were absent. Interestingly, 
pDC mediated activation of NK cells and CD8+ T cells were shown to be important for 
controlling MCMV and VSV, respectively. To this end, DCs can shape the activation 
of innate immune cells in a multitude of ways (32). In summary, DCs are now widely 
regarded for their central role in initiating immune responses towards foreign antigen 
and linking innate and adaptive limbs of the immune system (33). The diversity of DC 
function may be at least partially traced to the presence of several distinct DC subsets in 
blood and tissue. 
 
3.2 HUMAN DC SUBSETS 
3.2.1 Blood subsets: similarities and differences 
The assortment of human DCs in blood and other tissues is both well and poorly 
described. Human blood DCs may be separated into plasmacytoid DCs (pDCs) and two 
types of myeloid DCs (mDCs) based on unique expression of blood DC antigens 
(BDCA) (34-37). pDCs co-express CD303 (BDCA-2) and CD304 (BDCA-4), whereas 
one subset of mDCs displays CD1c (BDCA-1). DCs also express MHC-II (HLA-DR) 
(Table I). Immature pDCs have a round and non-dendritic morphology, but have been 
classified as DCs due to their ability to mature and activate naive T cells (38). pDCs 
also display, though not uniquely, the IL-3 receptor-α (CD123). mDCs share CD1c 
expression with a subset of B cells and CD11c expression with monocytes. While most 
mDCs are CD14-, a small frequency are CD14+ (37). The CD14+ to CD14- mDC ratio 
changes with certain toll-like-receptor (TLR)-ligand stimulations, although the reasons 
are poorly understood (W.C. Adams, unpublished data). A separate mDC subset 
expressing CD141 (BDCA-3) is notably proficient at loading and presenting exogenous 
foreign peptides on MHC-I in a process termed cross-presentation (39-42). Cross-
presentation describes the observation that immunization with soluble proteins or 
viruses that do not infect DCs leads to the induction of CD8+ T-cell responses 
(reviewed by (43)). Unless noted otherwise mDC will hereafter refer to CD1c+ mDCs. 
It is important to remark here that the current ternary division of blood DCs may 
oversimplify the actual subset heterogeneity.  
 
mDCs and pDCs share several classical DC features, such as efficient uptake of 
antigen, expression of multiple PRRs, and the ability to mature, migrate and activate 
naive T cells. But they differ in specific ways. First, mDCs are more efficient APCs 
when observed activating autologous T cells (44-46). Their repertoire of TLRs is 
distinct as well with mDCs expressing TLR1-8 and 10, and pDCs having TLR7 and 9. 
mDCs specialize in producing Th1 driving IL-12p70 and pDCs in the rapid and copious 
production of anti-viral IFNα/β (47-51) (Table I). pDC derived IFN-I and IL-6 also 
facilitate the formation of Ab-producing plasma cells after influenza exposure (52). 
Also, pDCs assist TLR-ligand induced activation of naive B cells through IFN-I, while 
mDCs do not seem to be as effective in this respect (53-55). It has been suggested that 
pDCs may be more potent cross-presenting cells than CD1c+ mDCs, but how pDCs 
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compare to canonical CD141+ mDCs has not yet been studied thoroughly (56). 
 
Before concluding this section it is important to compare human blood DC subsets with 
other mammalian vertebrates. In NHPs homologous mDCs and pDCs can be identified 
and isolated from blood (57, 58). In regard to mice, blood DCs may be subdivided into 
three types: pDCs that make high levels of IFNα, and two subsets of mDCs that are 
similar to the CD1c+ and CD141+ mDCs in humans (37).  
 
Table I. Human DC subsets 
Adapted from (59) and used with approval from publisher (intech.org) 
 
3.2.2 In vitro derived DC subset 
IL-4 and GM-CSF differentiate blood monocytes into a myeloid DC surrogate termed 
monocyte derived DC (MDDC) (60). MDDCs lose CD14 expression and gain CD1a 
and DC-SIGN (Table I). They also express MHC-II and are more potent pAPCs than 
monocytes. It is currently unknown whether MDDCs represent a single primary DC 
subset, but they may at least partly mimic skin resident interstitial dermal DCs (dDC) 
as they produce similar cytokines and express DC-SIGN (61). The ability to generate 
DCs from blood monocytes in vitro suggests that circulating monocytes have a certain 
level of plasticity in their differentiation program or fate. MDDCs are notable inducers 
of IL-12p70 in response to TLR-ligands (62), which indicates a role for these cells in 
driving Th1 type responses (Table I). 
 
3.2.3 Cutaneous subsets 
In the steady state DCs are dispersed throughout peripheral tissue including the skin. 
These cells also have a dendritic morphology and may be considered more 
differentiated than blood mDCs. Cutaneous DCs are normally divided into two subsets 
DC Subset Phenotype
Cytokines 
Produced Selection method Culture media
CD1c+ Myeloid DC CD1c+ (BDCA-1) IL-12p70
(mDC) CD11c+ TNF
CD14+/- IL-6
HLA-DR+
Plasmacytoid DC CD303+ (BDCA-2) IFN!/"
(pDC) CD304+ (BDCA-4) IL-6
CD123+ (IL-3Ra)
CD14-
HLA-DR+
CD1a+ IL-12p70 RPMI media
CD209+ (DC-SIGN) TNF 10 % fetal calf sera
HLA-DR+ IL-6 GM-CSF + IL-4
CD14-
CD209+/- (DC-SIGN) TNF RPMI media
CD14+/- IL-1 10 % fetal calf sera
HLA-DR+ IL-6
CD1a +/- IL-12p40
CD207+ (Langerin) TNF RPMI media
CD1a+ IL-1 10 % fetal calf sera
HLA-DR+ IL-15
IL-8
in
 v
itr
o
de
riv
ed
Monocyte derived DC 
(MDDC)
Monocyte isolation 
followed by 6 day culture 
with IL-4 and 
GM-CSF
C
ut
an
eo
us
 S
ub
se
ts
Dermal Interstitial DC 
(dDC)
Collagenase digestion of 
skin or GM-CSF induced 
migration from dermal 
skin layer
Epidermal Langerhans 
Cells (LC)
Collagenase digestion of 
skin or GM-CSF induced 
migration from epidermal 
skin layer
B
lo
od
 S
ub
se
ts
anti-CD1c magnetic 
microbeads with positive 
selection on Automacs 
(Miltenyi)
RPMI media
10 % fetal calf sera
GM-CSF
RPMI media
10 % fetal calf sera
IL-3
anti-CD304 magnetic 
microbeads with positive 
selection on Automacs 
(Miltenyi)
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based on the tissue in which they reside under steady state conditions: interstitial dDCs 
resident in the dermal layer, and Langerhans cells (LC) resident in the epidermal layer 
(29, 63). Both subsets express MHC-II and likely have a myeloid lineage. LCs display 
Langerin and CD1a, while the dDC population is more diverse based on expression of 
DC-SIGN, CD1a and CD14 (61, 64) (Table I). It is plausible that the dDCs defined 
here actually represents multiple unique subsets. The role each of these skin DCs play 
in detecting viral infection and initiating immune responses likely depends on both the 
route of challenge and the nature of the particular virus (35). It has been shown that 
dDCs, in particular the CD14+ subset, initiate humoral immunity (i.e. Ab-producing B 
cells) and LCs specialize in mediating cellular immunity (i.e. cytotoxic CD8+ T cells) 
(61). The notion that Langerhans cells potently induce T cells to proliferate has been 
appreciated for some time (65). pDCs are not normally found in the skin, but may 
migrate to the skin during inflammation and once there mediate immunity to viral 
infection and autoimmune diseases such as psoriasis (66, 67). While LCs and dDCs are 
found in human breast skin (64), the local and global distribution of these cells in this 
and other skin locations is largely unknown in mice or primates. Understanding 
differential local site distribution may provide insights into peripheral tolerance or 
immunity. These descriptive studies will be critical to perform in the future. 
 
3.3 LIFE HISTORIES 
Blood DC subsets arise from bone-marrow derived hematopoietic precursor cells, 
although their development is substantially less well defined that lymphocytes (68). 
Based on morphology and surface marker expression mDCs are thought to arise from a 
common myeloid precursor cell and pDCs from a lymphoid precursor (69). The 
expression of CD13 and CD33 on mDCs associates these cells with a myeloid lineage 
(37). The phenotype of pDCs circulating in blood together with the apparent lack of 
any pre-pDC subset suggests that these cells are fully developed in the bone marrow. 
DCs also differ in their life cycles (38, 70). mDCs enter the blood upon exit from the 
bone marrow and then migrate to and sample peripheral tissues. Circulating mDCs 
appear to remain plastic as incubation of these cells with GM-CSF and IL-4 induces the 
cells to differentiate further into phenotypically distinct subsets (71). The tissue 
environment likely plays a significant role in driving mDC differentiation. mDCs may 
then leave the peripheral tissue either constitutively (tolerance) or after activation by 
foreign antigen and migrate through the afferent lymphatics to the spleen or lymph 
nodes to activate T cells. In contrast, pDCs are scarce in peripheral tissue during the 
steady state but tend to migrate to sites of infection or inflammation. One clue that 
suggests blood DCs have not encountered antigen is that most isolated display an 
immature phenotype (44-46, 72). Both the frequency and function of circulating blood 
DCs has also been shown to be negatively affected by chronic HIV-1 infection (73, 74). 
These findings provide caution for studying DCs in humans since most are colonized 
by numerous latent viruses that may cause similar effects. Much remains to be learned 
about the life histories of blood and skin resident DCs. 
 
3.4 ACTIVATION 
Activation licenses DCs to induce tolerance or viral immunity. As has been discussed 
above, DCs located at peripheral sites (non-lymphoid tissue) in the steady state are 
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normally of an immature phenotype. These cells have high capacity to sample the 
extracellular environment and take-up antigen. Uptake of foreign or self-antigen alone 
may induce migration to lymphoid tissues. However, these cells will be in a quiescent 
state and will more likely induce a state of T-cell tolerance to the antigen. Because DCs 
can present peptides on MHC-I and MHC-II, tolerance will be regulated by both CD8+ 
and CD4+ T cells, respectively. Tolerance may take the form of ablation of these T 
cells (anergy) or induction of regulatory T cells (Treg). Conversely, when antigen is in 
the presence of a so-called ‘danger signal’ DCs undergo a maturation process in which 
upregulation of co-stimulatory markers licenses DCs to induce immunity (rather than 
tolerance) by activating naive T cells (29, 70). TCR and co-stimulatory signaling 
provided by mature DCs is commonly termed the two-signal model and is essential for 
controlling T-cell activation (75, 76). Thus, induction of DC maturation is an important 
checkpoint for driving either tolerance or immunity. Danger signals, often termed 
pathogen associated molecular patterns (PAMP), may be microbial products such as, 
bacterial cell wall components like LPS, nucleic acids (dsDNA or ssRNA), or CpG-
DNA motifs. However, commensal microbes also express PAMPs so the usage of 
‘pathogen’ is semantically ambiguous. Components from damaged cells or tissue that 
are released upon necrotic cell death are termed damage associated molecular patterns 
(DAMP). There are a number of well and poorly defined PRRs that sense foreign 
derived components. TLRs, cytosolic retinoic acid inducible–gene I (RIG-I)-like 
receptors (RLR), and the inflammasome are a few examples (reviewed in (77)). The 
licensing of DCs to activate lymphocytes is illustrated by the findings that TLR-ligands 
adjuvant protein-based vaccines in vivo to induce potent immunity to the immunized 
protein (78-80). DCs also make numerous cytokines such as, TNF, IFN-I, IL-1, IL-12, 
and IL-6 that drive innate immune responses and shape adaptive immune responses 
(32). 
 
Mature DCs may upregulate activating members of the B7 family (CD80 and CD86) 
that provide co-stimulation to optimally activate naive T cells through engagement of 
CD28. While DCs provide early co-stimulation to T cells via B7-CD28 signaling axis, 
B7 may also bind CTLA-4 on T cells later after activation (48 hours) (81). At this time-
point T cells convert from expressing CD28 to expressing CTLA-4 on their surface in a 
process that dampens further activation of the T-cell. DCs also upregulate MHC-II 
(HLA-DR) as well as CD40 that activates T cells through CD40-ligand binding. DCs 
may express other inhibitory receptors to control activation of T cells, such as the 
programmed death (PD)-1 ligands, PD-L1 and PD-L2. The role of the PD1 : PD-L1 
axis is not as well defined, although the expression of PD-1 on HIV-1 specific memory 
CD8+ T cells is correlated with an exhausted phenotype, increased apoptosis, and 
reduced control of infection (82). Transcription factor expression may also influence 
DC activation of T cells. For example, DC expression of the transcription factor Foxo3 
acts as one factor that can limit clonal T-cell expansion (83). How AdV can induce DC 
activation will be discussed in the chapter on AdVs. 
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4 T CELLS 
4.1 DEFINITION, LIFE HISTORIES, AND FUNCTION 
DCs are specialized to sense and interpret innate signals in order to activate and shape 
adaptive CD4+ and CD8+ T-cell responses. T cells begin life in the thymus as CD4-
/CD8- thymocytes expressing a diverse repertoire of αβ-TCRs generated by somatic 
gene recombination. Intricate negative and positive clonal selection processes generate 
mature naive T cells expressing either CD4 or CD8 that exit the thymus lacking TCR 
reactivity to self. In the periphery multiple mechanisms, such as promotion of naive T-
cell survival by presentation of self-pMHC and production of IL-7, regulate 
homeostatic maintenance of non-self reactive T cells with requisite functionality and 
diversity (84). Foxo1 has been suggested to be an integral transcription factor in 
regulating peripheral T-cell homeostasis by controlling IL-7 signaling and CCR7-
mediated homing (85). Notably, αβ-TCRs are unlike B-cell receptors (BCR) that 
undergo affinity maturation in peripheral secondary lymphoid organs, because TCR 
affinity for pMHC appears to be set in the thymus and to remain static in the periphery. 
Inherited allelic variation in the HLA repertoire (also termed HLA haplotype) further 
increases the diversity of potential antigen recognition and responses. 
 
After infection or vaccination, αβ-TCRs recognize cognate DC-displayed pMHC in a 
largely stochastic manner due to the rarity of αβ-TCR clones and the size of the animal. 
These interactions are further complicated by the low affinity and degenerate binding of 
pMHCs to TCRs. TCR recognition of pMHC is also restricted (86, 87), in the sense 
that pMHC-Is have a greater affinity for TCRs expressed on CD8+ T cells, whereas 
pMHC-IIs have higher affinity for αβ-TCRs expressed on CD4+ T cells. However, 
multiple mechanisms act to enhance the probability of successful encounters including, 
but not limited to, (i) the morphology of DCs that allows for simultaneous interactions 
with numerous T cells, (ii) low affinity integrin binding partners, such as lymphocyte 
function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-
1), that facilitate DC and T-cell attachment, and (iii) continuous recirculation of naive T 
cells in blood, peripheral tissue, lymphatic vessels, and secondary lymphoid organs 
where antigen becomes constrained in space and (iv) a network of stromal fibroblastic 
reticular cells (FRC) enhance the frequency of DC and T-cell contacts (88). CD4 also 
stabilizes the contact by binding MHC. Once the pMHC recognizes its cognate αβ-
TCR, T-cell activation may be initiated. Together, these and numerous other molecules 
proximal to the TCR-MHC complex form the immune synapse. As mentioned 
previously, T-cell activation signals are transmitted through ITAM-containing CD3 
side-chains in proximity to the TCR and quantitatively enhanced by CD28 co-
stimulation. Subsequent downstream intracellular signaling pathways converge to 
activate three main transcription factors namely, nuclear factor κ-light-chain enhancer 
of activated B cells (NF-κB), nuclear factor of activated T cells (NFAT), and activator 
protein-1 (AP-1) that drive proliferation and cytokine production (89, 90). In this way, 
TCR-activation at the polarized synapse on the naive T-cell leads to a clonal burst (i.e. 
proliferation) and induces other functions specific to each T-cell subset. While 
activation of naive T cells most likely occurs in lymphoid tissues, memory T cells may 
be activated in lymphoid and peripheral non-lymphoid tissues near the site of certain 
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infections like HSV-1 (91). In general terms, activated CD8+ T cells are termed CTLs 
because they can kill (i.e. induce apoptosis of) infected (intracellular microbes) or 
cancerous targets cells. CD4+ T cells provide critical ‘help’ to various cells, including 
CD8+ T cells (92). This help in concert with IL-2 provide signals to facilitate optimal 
priming of CD8+ T-cell responses that can establish durable cellular immunity (7). 
Thus, the induction of immunological cellular memory depends largely on priming of 
CD4+ T-cell helper (Th) responses (93, 94). These functions make CD4+ T-cell 
responses crucial for vaccination (7), which is why we have focused on this subset in 
this thesis. Numerous intrinsic and extrinsic signals regulate CD4+ T-cell activation 
and differentiation, and for reasons discussed later, we have narrowed our studies to 
intrinsic regulation by CD46. The role of this receptor in modulating T-cell function 
will also be discussed in detail. 
 
In conjunction with antigen-specific activation, inherently plastic naive CD4+ T cells 
differentiate into at least four known peripheral effector lineages (95). Seminal work by 
Coffman and colleagues first described two terminally differentiated Th1 and Th2 
effector subsets (96). Th1 cells are induced by IL-12p70, express IFNγ and the 
transcription factor T-bet, and control intracellular pathogens like viruses (92). Th2 cells 
express IL-4 and trans-acting T-cell specific transcription factor GATA-3, and control 
external pathogens like worms via humoral immunity. Potential drawbacks of these 
responses may be the induction of autoimmune-induced pathology and allergy, 
respectively. Still, these effector cells are important components of an adaptive immune 
response. As an example, the induction of polyfunctional Th1 responses correlates with 
vaccine protection against Leishmania major in mice (97). As often the case in biology 
the Th1/Th2 paradigm is likely too simplistic. More recently, additional effector CD4+ 
T-cell lineages have been identified including induced regulatory T cells (Treg) and 
Th17 cells, which express forkhead box P3 (FoxP3) and RORγt transcription factors, 
respectively (98). Tregs keep Th1 and Th2 cells in check, whereas Th17 cells control 
extracellular pathogens at mucosal surfaces by producing IL-17 and IL-22. CD4+ T 
cells also generate long-lived effector and central memory subsets that persist and are 
maintained after viral clearance. A final subset, follicular helper T cells (TFH), is present 
in lymph node associated germinal centers and directs B-cell Ab responses via IL-4 
signaling (99). It is not entirely clear how these effector subsets arise, especially given 
that TCR-clone specificity of the original antigen-activated CD4+ T-cell ostensibly 
needs to be preserved. The prevailing “one cell-multiple fates” model is supported by 
an expanding body of evidence (100). Asymmetric T-cell division upon initial 
activation results in both effector and memory T cells during the first division and 
provides one cellular mechanism (101, 102). The finding that transplantation of a single 
naive CD4+ T-cell clone into a recipient mouse was sufficient to induce multiple T-cell 
fates also supports this model (103). DC signaling may also drive these fate decisions, 
though there is much to learn regarding the precise mechanisms at work (104). The 
concept of fate determination are discussed here because it will be critical to more 
accurately define the activation and differentiation steps in the life of CD4+ T cells in 
order to design the next generation of cellular and Ab mediated vaccines. While certain 
vaccine adjuvants have tendencies to drive particular CD4+ T-cell effector fates (78), 
many molecular and cellular determinants must still be elucidated. 
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4.2 CD46: DEFINITION AND FUNCTION  
4.2.1 A complement and viral receptor 
Complement plays multifaceted roles in rapid destruction of microbial invaders and in 
shaping innate and adaptive immune responses (3, 105-108). An important requirement 
of complement is protection of healthy host cells from opsonization and elimination. 
Several complement regulatory proteins, such as decay accelerating factor (DAF or 
CD55), protectin (CD59), and membrane cofactor protein (MCP or CD46), are 
displayed on cellular membranes and control how complement components distinguish 
between healthy cells and foreign or apoptotic cells. As such, most nucleated cells, 
including all immune cells in peripheral blood, express CD46 (44). The extracellular 
structure of CD46 contains four short consensus repeats (SCR) (Figure 1). CD46 serves 
as a cofactor for the cleavage of complement proteins C3b and C4b. While wild-type 
mice do not express CD46, transgenic mice expressing human CD46 have been 
generated and facilitated the study of CD46 function in vivo (109). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic of the structure of CD46 and binding location of AdV-35 and 
C3b. 
 
CD46 has been termed the pathogen magnet as at least seven human pathogens use 
CD46 as a primary attachment receptor, including AdV-35 (110). Upon engagement 
several CD46-using pathogens reduce CD46 expression: AdV-35 (72, 111), AdV-11p 
(112), Measles virus (MV) (113, 114), Human Herpes Virus-6 (HHV-6) (115), 
Neisseria gonorrhoeae (116), and Streptococcus pyogenes (117, 118). Downregulation 
of CD46 leads to increased sensitivity to complement mediated lysis, indicating that 
this regulatory protein plays an essential role in protecting healthy host cells from 
complement elimination (114, 119). In lymphoid cells, CD46 internalization does not 
occur constitutively but is induced when the receptor is engaged, whereas in myeloid 
cells downregulation of CD46 may be constitutive (120). CD46 contains a cytoplasmic 
Tyr-Arg-Tyr-Leu membrane trafficking motif that mediates internalization (121). In 
summary, receptor downregulation appears to be conserved amongst CD46-using 
pathogens. The capacity of surface CD46 to internalize upon ligation may also indicate 
intrinsic signaling potential. 
 
4.2.2 A regulator of T cells 
Emerging evidence is defining CD46 as an important regulator of T-cell function (122-
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124). It was originally observed that engagement of CD46 by either MV or 
recombinant C3b protein leads to lower LPS-induced IL-12 production in monocytes 
(125). The authors offered this finding as one mechanism to explain MV-mediated 
immune-suppression. The data also implied that CD46 might be linked to downstream 
signaling pathways in immune cells. After the discovery that CD46 regulated IL-12 
production, Wang et al. found that CD46 was able to transmit extracellular signals to 
the cytoplasm through its two cytoplasmic tails (cyt) (126). This finding provided much 
of the impetus for studying the function of CD46 on immune cells. Further supporting 
the role of CD46 signaling in regulating innate immune cells, it was shown that CD46 
engagement blocked IL-12 in macrophages (127) and enhanced IFNγ-induced nitric 
oxide production in macrophages (128). Alternative slicing of CD46 generates four 
isoforms with each expressing one of two different cytoplasmic tails. The cyt-1 isoform 
is 16 amino acids (AA) and the cyt-2 isoform is 22 AA in length (Figure 1). The cyt-1 
isoform of CD46 contains a putative tyrosine phosphorylation site for protein kinase C 
and casein kinase 2, whereas the cyt-2 isoform is tyrosine-phosphorylated by src 
kinases (in particular, Lck) in T cells (126). We have found using RT-PCR analysis that 
cyt-1 and cyt-2 are expressed at similar ratios in peripheral lymphocytes including, 
CD4+ T cells (W.C. Adams, unpublished data).  
 
Numerous reports in the literature attribute both negative and positive regulatory 
properties of CD46 on TCR-dependent activation of CD4+ T cells. Initially, Marie et 
al. generated transgenic mice expressing human CD46 to study the role of CD46 in 
mediating T-cell activation in vivo (109). In this report, mice were generated that 
expressed one or both of the cyt isoforms. The effect of CD46 engagement on T-cell 
activation was dependent on cyt expression. Importantly, when both cyt tails were 
expressed, which more closely resembles expression in human CD4+ T cells, IL-2 but 
not IFNγ production was reduced. We have confirmed that CD46 engagement by either 
mAbs or rAdV-35 blocks IL-2 and not IFNγ in human CD4+ T cells (72). Nuclear 
translocation of NF-κB, a crucial factor for IL-2 gene transcription (129), was also 
inhibited by CD46 engagement (72). CD46 also induces expression of negative 
regulators of IL-2 transcription: inducible cAMP early repressor/cAMP response 
element modulator (ICER/CREM) (130, 131). However, it is unclear how this may 
interfere with early IL-2 production since ICER/CREM was expressed days after 
activation and correlated temporally with a switch from IL-2 production to IL-10 in 
type-1 regulatory T cells (Tr1) (discussed below). CD46 may also regulate T-cell 
proliferation as was shown initially by Marie and colleagues (109). Similarly, CD46 
engagement causes abortive proliferation as a result of defective akt/surviving signaling 
pathways in CD4+ T cells (132). The effector functions of T-cell subset displaying γ/δ-
TCRs seems to also be inhibited by engagement of CD46 (130).While these effects of 
CD46 seem to mainly downregulate T-cell function, this may not always be the case. 
For example, CD46 ligation has been shown to increase proliferation (133) and IL-2 
and IFNγ production (134). These differential effects may be driven by cyt expression, 
as cyt-1 expression promotes T-cell activation, while cyt-2 causes inhibition of T-cell 
activation (135). The apparent discrepancies in these data are not well understood. 
However, as discussed by Meiffren et al., the discrepancies may be due to the strength 
of the provided CD3/CD28 signal (132). Different CD46 mAb clones may also induce 
markedly different signaling; whereas a SCR1 targeting mAb blocked proliferation, a 
SCR2 mAb had no effect (72).  
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CD46 engagement has been implicated in driving the induction of Tr1 cells. 
Stimulation of CD4+ T cells with anti-CD3 and CD46 mAbs with exogenous IL-2 
causes the induction of IL-10 producing Tr1 cells, which can suppress bystander T-cell 
proliferation (136). These results were confirmed with more relevant CD46 binders 
C3b and S. pyogenes M protein (137). Numerous functions have been attributed to 
these CD46-induced Tr1 cells. First, the cells express Granzyme A and may kill 
autologous target T cells, monocytes, and DCs in a perforin dependent manner (138). 
Second, they can attenuate mycobacterium-specific memory T-cell responses, but 
surprisingly this suppression occurs independent of IL-10 (139). Third, while CD46-
induced Tr1 cells reduce T-cell activation and induce IL-10, they still allow for the 
maturation of DCs (140). And fourth, these Tr1 cells support B-cell Ab responses in an 
IL-10 dependent manner without enhancing B-cell proliferation (141). Thus, this 
current evidence suggests that CD46-induced regulatory T-cell responses may serve to 
downmodulate Th1 responses (142). Whether CD46-induced Tr1 cells are terminally 
differentiated effectors cells analogous to Th1 or Th2 cells has not been rigorously 
tested. In addition how these cells compare to canonical FoxP3+ induced-Tregs is also 
not known.  
 
The restriction of CD46 expression to primates constrains investigations in vivo. Yet 
certain human diseases have been helpful as CD46 is associated with dysregulated 
immune responses in patients with autoimmune disease. CD4+ T cells from patients 
with multiple sclerosis (MS) have a diminished capacity to make IL-10 after CD46, but 
not CD28, stimulation (143). Similarly, patients with rheumatoid arthritis (RA) show a 
defective switch from IL-2 to IL-10 producing Tr1 cells induced by CD3 and CD46 
engagement in the presence of exogenous IL-2 (130). These two studies suggest that 
MS and RA autoimmune diseases may provide suitable models for studying CD46 in 
vivo together with human CD46-transgenic mice. 
 
While most of the CD46 discussion thus far has focused on CD4+ T cells, CD46 
engagement also modulates CD8+ T cells in unique ways that merit discussion here. 
CD46 blocks CD3/CD28 induced IFNγ and also interferes with polarization of the 
immune synapse and recruitment of CD3 (144). A similar effect was seen for NK cells 
as CD46 ligation negatively impacted the recruitment of perforin and their ability to kill 
target cells (144). This report raised an important question regarding CD46 signaling: 
how does cis- versus trans- engagement of CD46 affect downstream signaling? These 
authors found that only soluble CD46 ligands caused these effects with the anti-
CD3/CD28 mAbs immobilized onto a bead, which helps to explain the inefficient 
polarization. A follow-up report provides a potential mechanism. In this model, CD46 
can compete for lipid rafts to alter the T-cell polarity towards the site of CD46 ligation 
(145). Still, more needs to be learned about the effects of CD46 on T-cell polarization, 
particularly with respect to CD4+ T cells and how improper polarization may affect T-
cell activation by DCs (146). Whether CD46 may also control fate decisions should be 
elucidated.  
 
An ever-expanding body of literature is more accurately defining the roles of CD46 in 
regulating innate and adaptive immune cell function. It is particularly interesting since 
these studies have collectively illustrated how (i) complement regulates the other facets 
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of the immune system and (ii) how pathogens may have hijacked CD46 signaling 
networks to regulate host immune responses. However, it is important to note that there 
remains significant lack of clarity about how complement factors versus pathogen 
binding may impact T-cell function. Cardone et al. have recently found that activated 
CD4+ T cells may be a significant source of C3b, which may indicate that these cells 
can regulate their own function via CD46 (130). Much of the work studying this 
receptor has been done using a variety of mAbs and how they replicate natural or 
foreign ligand binding is not entirely clear. Since mice do not express a CD46 
homologue, an emphasis should be placed on performing these studies in humans and 
NHPs. The temporal aspects of CD46 engagement and subsequent signaling may also 
play a significant role in the type of effect caused. In summary, the currently available 
literature is helping to paint the complex picture of the role of CD46 in immune 
regulation. 
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5 ADENOVIRUS 
AdVs have been extensively studied since the 1950s when they were isolated from 
human adenoids (or pharyngeal tonsils) (147). As mentioned, the human AdV genus 
contains at least 50 different types divided into six species (A through F) and cause 
numerous acute human diseases (148, 149). Species B may be divided into two species 
based on receptor usage (referred to as B1 and B2) (150). Classification into serotypes 
was traditionally accomplished by testing their sensitivity to neutralization by different 
human antisera, and division into species by their capacity to agglutinate erythrocytes 
from different species. AdVs are now mainly classified based on sequence data and 
phylogenetic analysis. AdV species may be generally correlated with clinical disease. 
In this thesis, we have performed a comparative analysis between AdV-5 (species C) 
and AdV-35 (species B). In this section the basic virological and clinical applications of 
AdVs will be discussed. 
 
5.1 STRUCTURE 
The AdV virion has an icosahedral non-enveloped capsid with fiber spikes protruding 
from each vertice that encapsulates a double stranded linear DNA genome (Figure 2A-
B). The complete high resolution structure of the AdV virion, which has a mass of 
∼150 mega Daltons, a diameter of ∼90 nm/∼900 Ångströms, and contains ∼1x106 AA, 
has recently been solved using cryo-electron microscopy and x-ray crystallography 
(151-153) and provides critical insights into the virology of AdV. The genome 
organization and capsid structure are relatively conserved amongst AdV species, but 
receptor usage, cellular and tissue tropism, and activation of immune cells differs. 
There is a strong relationship between the AdV capsid structure and its function in 
mediating steps in the virus life cycle (149). AdV particles are especially stable due to 
the capsid structure and absence of lipid envelope, as is exemplified by the particle’s 
retention of infectivity after multiple freeze-thaw cycles. The stability of AdV particles 
also largely determines cell-cell spread, host-to-host transmission, and tissue tropism. 
The viral structural components can be categorized as major, minor, and genomic core 
associated proteins. These basic building blocks of the AdV capsid will now be 
discussed. 
 
5.1.1 Major proteins 
The complex icosahedral capsid contains three groups of major proteins: (i) two-
hundred-forty trimeric hexons that form the 20 pseudo-equilateral triangular capsid 
facets, (ii) twelve pentameric penton-bases that form at each capsid vertice, and (iii) 
twelve trimeric fibers that are anchored in the penton base pentamers and protrude from 
the vertice (Figure 2A-B). There are four different hexon proteins that form in groups 
of nine (GON) on the planar face and in groups of six (GOS) surrounding the penton 
base. Hexon proteins contain hypervariable regions (HVR) exposed on the outer-face 
and may represent the primary neutralizing targets. This was shown experimentally 
when chimeric rAdV-5 vectors with HVRs from other serotypes evaded AdV-5 
neutralizing Abs (154). The pentameric penton base contains a central pore in which 
the fiber is positioned non-covalently. In solving the high resolution structure, Reddy et 
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al. observed that the penton base was highly flexible and allowed for different pore 
sizes in order to accommodate different fibers (153). These data shed light on how the 
chimeric vectors used in this thesis remained stable. Finally, the penton base also 
contains RGD loop motifs that interact with cellular integrins to mediate AdV entry via 
endocytosis (155, 156). The fiber protein is a complex polypeptide that consists of three 
parts: (i) a tail, (ii) a shaft, and (iii) a knob. The shaft has three intertwined proteins and 
the length varies between AdV species. For example, the AdV-5 shaft is nearly twice 
the length of AdV-35. The trimeric knob polypeptide that is located at the C-terminus 
of the shaft mediates binding to the receptor, such as the binding between AdV-35 and 
CD46 (157). It is thought that most of the virus-cell interactions occur via the major 
capsid proteins. 
 
A   B 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A) Electron micrograph of rAdV-5 particles used in these studies (courtesy 
of Kjell-Olof Hedlund; Swedish Institute for Communicable Disease Control). (B) 
Schematic of major AdV capsid proteins and structure.  
 
5.1.2 Minor and genomic core proteins 
In addition to the three groups of major proteins, the capsid also contains a number of 
minor proteins: (i) IIIa, (ii) VI, (iii) VIII, and (iv) IX. These minor proteins have also 
been termed ‘cement proteins’ for their function in stabilizing the assembled major 
proteins (151-153). IIIa is located on the inner capsid surface and acts to support penton 
bases and GOSs. There are at least two-hundred copies of protein VI that may be 
located within the hexon trimers. At least one-hundred-twenty VIII proteins are located 
on the inner capsid surface and serve to support GONs, but also link GONs and GOSs 
together. Finally, a complex network of IX proteins laying within the space between 
hexons support the capsid and may help orchestrate the final virion assembly. Other 
functions relating to cell binding have been associated with these minor proteins. For 
example, a specific motif within protein VI mediates trafficking of the virus particle to 
the nucleus by supporting microtubule-dependent movement (158). Protein VI as also 
been implicated in the later life cycle of AdV by mediating lysis of the endosomal 
membranes (159). Finally, the genomic core contains a further five proteins associated 
with the DNA genome: (i) V, (ii) VII, (iii) µ, (iv) IVa2, and (v) a terminal protein. The 
final protein within the genomic core is termed the 23K virion protease and is not 
associated with the viral nucleic acid. 
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5.2 VIRAL LIFECYCLE 
The AdV lifecycle typifies that of most viruses in that it may be separated into the 
following three phases: (i) virus entry (attachment, penetration, and uncoating), (ii) 
genome replication (transcription and translation), and (iii) virus release (virion 
assembly, maturation, and exit). However, it is important to note here that the details 
may differ depending both on cell type and AdV species. For this reason, one must be 
careful to extrapolate cell line data to DCs that are non-dividing and non-adherent. In 
the first step, the AdV knob binds with high affinity to a primary attachment receptor. 
Attachment to this receptor as well as interactions between the penton base and cellular 
integrins initiate penetration of the plasma membrane and subsequent clathrin-mediated 
endocytosis (155, 160). The ensuing fusion of clathrin-coated pits with endosomes 
enables AdV particles to uncoat and then escape the endosome concurrent with their 
acidification. As endosomes are generally considered extracellular, this entry into the 
cytoplasm marks entry into the cell. The virus particle containing its nucleic acid (linear 
dsDNA) then binds the microtubule associated molecular dynein motor, which 
facilitates retrograde transport along microtubules to the nuclear membrane (161). 
Formation of nuclear membrane pore complex facilitates entry of the nucleic acid into 
the nucleus where replication occurs (162). The AdV nucleic acid replicative cycle is 
generally divided into early and late phases based on replication of early and late genes, 
respectively. Synthesis of both early and late AdV mRNA transcripts is performed by 
the host cell RNA polymerase II, which is known to occur since α-amanitin enzyme 
blocks mRNA synthesis (163). The use of host cell machinery makes AdV genomic 
replication less prone to errors and subsequent mutation. Deletion of AdV early genes 
strongly attenuates replication, which indicates the important of these genes in the AdV 
life cycle. The late phase of transcription includes synthesis of the AdV structural 
proteins, which will be discussed at greater length in the next section. Mature virions 
incorporating the genome are then released from the plasma membrane through lysis. 
In regards to the kinetics of the AdV lifecycle, AdV entry occurs very rapidly (minutes 
to hours), while DNA replication begins hours later. 
 
5.3 ATTACHMENT RECEPTORS 
Receptor binding provides the initial mechanism of viral attachment to cells. AdVs use 
a variety of cellular attachment receptors that are determined both by cell type and AdV 
type (reviewed by (148)). Receptor usage may also depend on the host species – such 
as between human and mice. Therefore, in this thesis we will focus on the receptors 
expressed by human DCs that have been or may potentially be implicated in rAdV 
infection.  
 
5.3.1 AdV-35 receptors 
It is well established that species B AdV-35 uses the complement regulatory protein 
CD46 to attach to and infect multiple human cells (157, 164, 165). Due to the 
ubiquitous expression of CD46 on numerous cell types rAdV-35 may infect or at least 
bind to a wide range of cells. CD46 may also be a suitable receptor since it is 
endocytosed upon ligation, which would give the virus a means to gain entry into the 
cell (120). For these reasons in addition to the immuno-modulatory properties of CD46, 
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it is perhaps not surprising that several human pathogens have evolved to hijack this 
receptor for primary attachment (110). The trimeric fiber knob protein mediates high 
affinity and avidity binding of AdV-35 to a region within the extracellular SCR1 and 2 
domains of CD46 (157, 165, 166). AdV-35 uses CD46 to infect primary pDCs and 
mDCs (44). In fact, all species B AdVs probably use CD46 except types 3 and 7 (167). 
Not only do species B AdVs bind CD46, but they may also dramatically affect CD46 
conformation like has been shown for AdV-11 (168).  
 
5.3.2 AdV-5 receptors 
In contrast to the well defined case of AdV-35, receptor(s) used by the species C AdV-
5 are less clear. This is particularly apparent with respect to DCs. The coxsackievirus-
adenovirus receptor (CAR) is the described receptor for rAdV-5 on epithelial cells 
(169-172). Lack of expression of the tight junction protein CAR on the apical side of 
polarized epithelial cells may make it difficult for rAdV to access this receptor. For 
AdV to infect epithelial cells via CAR in vivo would ostensibly require the breakdown 
of the epithelial barrier. Although this scenario remains plausible, CAR-independent 
infection has been noted in epithelial cells (173), hepatocytes (174), fibroblasts (175, 
176) and primary DCs (44, 177-179). rAdV-5 mutants with ablated CAR binding also 
retain their ability to infect murine DCs (177), which supports our reports that AdV-5 
infects human blood DCs in the absence of CAR expression (44, 180). Johansson et al. 
isolated the iron binding protein lactoferrin (Lf) as the component from tear fluid that 
facilitates species C AdV infection of ocular epithelial cells in vitro (173). Lf also 
enhances rAdV-5 infection of primary human blood and skin DC subsets (180). High 
affinity interactions between AdV-5 hexon proteins with coagulation factor X (FX) also 
may enable efficient transduction of hepatocytes and mediate liver tropism (181, 182). 
FX and FIX also enhance AdV-5 binding to and transduction of epithelia cells in a 
heparin dependent manner (183). It is currently unclear to what extent these soluble 
factors mediate infection of human DCs in vivo. Receptor usage may be dependent on 
the route of inoculation, so it may not be surprising that AdV vectors bind coagulation 
factors with artificial intravenous administration. These studies also illustrate that 
cellular tropism may be determined by binding events that occur independent of the 
classical AdV knob-receptor interactions. For example, a Lys-Lys-Thr-Lys (KKTK) 
AA motif within the rAdV-5 fiber-shaft facilitates murine DC infection in a heparin 
dependent manner (177). This motif however does not facilitate AdV-5 infection of 
liver cells in vivo (184). Whether this receptor usage also exists in human DCs should 
be analyzed. 
 
5.3.3 Other AdV receptors on DCs 
The co-stimulatory receptors, CD80 and CD86, involved in the antigen presentation 
process have been suggested as receptors for AdV-3 (185, 186). These findings are 
relevant here since DCs display these markers whereas most other cells do not. As 
discussed earlier, surface CD80 and CD86 levels increase on DCs during phenotypic 
maturation. The usage of CD80 and CD86 by AdV-3 to infect DCs still needs to be 
confirmed experimentally. However recent evidence suggests that these are not the 
receptors, but rather that AdV-3, -7, -11, and -14 bind desmoglein-2 with high affinity 
to infect epithelial cells (187). It is unknown if this receptor is expressed on human DCs 
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and facilitates infection, but this report highlights how receptor usage may differ 
between cell types since AdV-11 also binds CD46 (168). A novel receptor for AdV-37 
has also been identified as sialic acid binding residues in the AdV-37 knob mediate 
binding to GD1a glycans (188). In light of this finding and the observation that AdV-37 
derived knob proteins enhance AdV-5 infection of myeloid APCs it will be interesting 
to determine whether this receptor is relevant for mediating infection of human DCs 
(189).  
 
5.3.4 Secondary AdV receptors 
A secondary interaction with cellular αv/β3 and αv/β5 integrins and Arg-Gly-Asp 
(RGD) motifs of the AdV penton bases facilitates membrane penetration and 
internalization of AdV particles (156). While RGD motifs are not required for cell 
attachment they seem to be essential for efficient entry (190). It has been suggested that 
αv/β5 integrins may even be sufficient to allow rAdV infection when CAR is not 
present (191), but this finding should be confirmed on human DCs. However, mutant 
rAdVs with ablated integrin binding retain their ability to infect murine DCs, which 
indicates that such interactions are not essential on DCs (177). It will be important to 
further elucidate the role of integrins in mediating rAdV infection of DCs, particularly 
since the expression may differ between DCs subsets and host species. 
 
5.3.5 Genetic retargeting of AdV to DCs 
Retargeting rAdV to use unnatural receptors to infect specific cell types has also been 
studied. This has been accomplished by genetic modification of the capsid structure or 
addition of soluble proteins. As an example, increased vector transduction of DCs has 
been tested by genetically modifying rAdV vectors to bind CD40 (192) or DC-SIGN 
(193, 194). Targeting DCs in this manner led to greater transduction efficiency of DCs 
by retargeted rAdV vectors compared to unmodified vectors. These reports are 
reminiscent of how Lf also enhanced infection through DC-SIGN (180). AdV particles 
modified to express the hexon-derived RGD motif also had enhanced infectivity of 
mouse DCs (195). These studies indirectly demonstrate that importance of receptor 
usage in determining cellular tropism of AdVs and may have clinical applications. 
 
5.4 INNATE IMMUNE RECOGNITION OF ADENOVIRUS 
5.4.1 Viral nucleic acid recognition 
We have reported that rAdV-35 induces DC maturation comparable to LPS or TLR7/8-
ligands (44, 72) and cytokines, such as IFN-I, in pDCs (44). These findings together 
indicate that DCs may sense and respond to AdV infection.  
 
As such, how might innate immune cells recognize AdV? Numerous PRRs have been 
implicated in the recognition of viral or bacterial dsDNA (196). In the TLR family, the 
endosomally expressed TLR9 binds dsDNA and induces IFN-I. Longer endosomal 
retention time and complexing with interferon regulatory factor-7 (IRF-7) of TLR9 
ligands in pDCs are proposed mechanisms for why these cells are particularly efficient 
at producing IFN-I (197, 198). The endosomal location of TLR9 may be one 
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mechanism that allows this receptor to distinguish between host and pathogen 
associated DNA (199). The rationale being that host DNA would not gain entry to the 
endosome, whereas viral derived DNA could. In human innate immune cells TLR9 
expression is thought to be restricted to pDCs. To that end, the induction of IFN-I in 
pDCs by other DNA viruses, namely HSV-1 (200) and HSV-2 (201), is dependent on 
TLR9 signaling. CD46-using AdVs also induce IFN-I in human PBMCs through 
endosomal TLR9 (202, 203), which makes sense given that AdV enters endosomes 
during entry. Genomic content may also influence the capacity of AdVs to activate 
immune cells. For example, the greater frequency of immunosuppressive unmethylated 
CpG motifs in the AdV-5 genome has been shown to be one factor that makes this 
virus less stimulatory in human PBMCs (204). It would be interesting to follow-up on 
this analysis with other species of AdV.  
 
Other PRRs may enable cells that do not express TLR9 to sense AdV. In fact, TLR-
dependent and TLR-independent pathways mediate the recognition of pathogen 
associated DNA and initiation of immunity (196, 205). Data from the dsDNA HSV-1 
has shown that IFN-I is induced by TLR-dependent and TLR-independent mechanisms 
in mice (200), which suggests that DCs may not be the only mediators of innate 
responses to dsDNA viruses. AdV induction of IFN-I in pDCs was dependent on TLR 
signaling, whereas in other cell types IFN-I was independent of TLRs (206). Splenic 
mDCs were shown to be the major source of IFN-I in vivo following AdV-3 or AdV-5 
immunization (207). These authors also found that IFN-I induction occurred 
independent of TLR and cytosolic nucleic acid receptor recognition. While IFN-I 
required the IRF-7, IRF-3 was not required. Another group also observed that IFN-I 
was not dependent on TLR signaling, but required IRF-3 (208). Myeloid differentiation 
primary response gene (MyD88), a universal TLR signaling adaptor protein, was 
recently found to be partially involved in the induction of CD8+ T-cell responses by 
AdV immunization (209). Since in this study TLRs – including TLR3-4 which can 
signal independent of MyD88 – were not found to be required, the significance of this 
finding is not entirely clear. Whether, as the authors assert, this finding implies that 
multiple innate signaling pathways are thus induced by AdV remains to be shown. 
Another study has also confirmed that TLRs, as well as inflammasome activation, do 
not play a substantial role in driving CD8+ T-cell responses in AdV infection (210). 
However, transgene-specific CD8+ T-cell responses are mounted in the absence of 
intact IFN-I signaling, which suggests that IFN-Is do not play a critical role in 
mediating cellular responses (211).  
 
Potential cytosolic DNA receptors have also been identified, which include DNA-
dependent activator of IRF (DAI) and absent in melanoma 2 (AIM2) (212, 213). 
Sensing by DAI leads to the induction of IFN-I, whereas the inflammasome associated 
AIM2 leads mostly to IL-1 production. Other evidence also indicates that AdV DNA 
and membrane penetration can activate the inflammasome to induce pro-inflammatory 
cytokine (IL-1β) responses (214, 215). The role of these cytosolic dsDNA sensors 
remains controversial and more work will need to be done to confirm the reported 
findings. A central component of cytosolic recognition may be the family of high-
mobility group box (HMGB1-3) proteins that bind a diverse array of pathogen 
associated nucleic acids, including dsDNA (216). HMGB-1 knockout mice have 
defective cytosolic receptor and TLR recognition of DNA. Mouse embryonic 
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fibroblasts from these mice failed to make IFN-I upon B-DNA, HSV-1, VSV, or CpG 
ODN stimulation, indicating that HMGB is essential for nucleic acid recognition. It is 
not currently known how HMGB binds nucleic acids and affects PRR signaling 
through cytosolic receptors. While PRRs sense viral infection directly, another possible 
scenario is that DCs respond to necrotic neighboring cells and the danger signals they 
release (i.e. DAMPs). Since some DNA viruses like AdVs are lytic viruses, it is 
plausible that these pathways may play a significant role in mediating immunity. 
 
5.4.2 Alternative innate AdV recognition 
In addition to viral genome, viral nucleic acid transcripts and capsid proteins may also 
induce innate immune responses. For example, virus associated RNA (VA-RNA) 
intermediates synthesized by RNA polymerase III may also contribute to systemic IFN-
I production after AdV immunization (217, 218). Interestingly, the presence of VA-
RNA correlated specifically with a second wave of IFN-I production after infection. 
Pathogen attachment to cells has been implicated in the recognition of AdVs. Binding 
of AdV penton base RGD motifs to β3-integrins induced IL-1α independent of 
membrane penetration (219). In this way, mouse macrophages act as major initiators of 
innate immune response towards AdV vectors in vivo. Furthermore, interactions 
between AdV-37 RGD motifs and cellular integrins have been shown to facilitate the 
recruitment of leukocytes in keratitis by inducing chemokine production (220). These 
reports highlight how AdV interactions with receptors may facilitate infection and 
triggering of innate immune responses independent of cell infection (221). 
 
A better understanding of innate immune recognition of AdVs in vivo is required. 
Unnatural tropism of human AdV in mice may add an additional layer of complexity in 
translating these findings to human. Recognition of AdV may also be dramatically 
different in different subsets of DCs depending on PRR repertoires. DC receptors and 
signaling pathways leading to phenotypic maturation seem to be substantially less well 
defined compared to those leading to IFN-I production. 
 
5.5 GENERATION OF REPLICATION INCOMPETENT VECTORS 
Replication incompetent rAdV vectors, deleted of earlier genes (e.g. E1, E3, and/or 
E4), can be efficiently generated in mammalian packaging cells lines (222). PER.C6 or 
293-ORF6 provide deleted early genes in trans that produce rAdV-5 and rAdV-35 
vectors with a capacity for foreign transgenes of up to 7.5 kb under control of a CMV 
promoter (223). Optimized promoter elements further enhance transgene expression. A 
thorough analysis of promoters of different origins found CMV promoters to be the 
most active in human DCs (224). However, these authors noted that promoter type 
strongly affected transgene expression and that promoter activity was dependent on cell 
type. Cell lines may thus neither accurately represent promoter activity nor predict gene 
expression in primary immune cells. Viral expression cassettes typically also include 
SV40 polyadenylation signals to further enhance expression of the transgene. 
Transgenes encoding fluorescent proteins (e.g. green fluorescent protein or GFP) can 
be used to follow viral infection. These current methods result in the generation of high 
viral titer stocks with severely reduced viral replication.  
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5.6 IN USE AS VACCINE VECTORS 
5.6.1 Background 
rAdVs continue to steadily gain prominence as they are the most widely used vectors in 
gene therapy and vaccine trials (14, 17, 225). Their use as vaccine vectors was driven to 
a large degree by studies showing that rAdVs induce higher a magnitude of insert 
specific cellular and humoral responses (i.e. immunogenicity) in NHPs compared to 
other viral vectors (226, 227). A variety of ‘prime-boost’ regimens have been tested to 
further enhance immunogenicity. Such regimens are termed (i) homologous when 
multiple administrations are given with the same rAdV or (ii) heterologous when 
multiple administrations are given of different rAdV types, or rAdV with DNA 
plasmids. The advantage of rAdVs also lies in their extensive characterization and in 
the ability to produce high titers of replication incompetent virus encoding relatively 
large foreign gene inserts. AdV are also naturally adjuvanted unlike DNA plasmids or 
protein subunit vaccines and transduce many cell types, which leads to extensive 
transgene expression in vivo. In addition, rAdV vectors have been shown to be safe in 
both pre-clinical toxicology (228, 229) and clinical trials (230-233). Finally, AdV genes 
have been found to not integrate in the host genome and AdV particles are cleared after 
three months (229). 
  
The use of rAdVs in NHP and human trials has yielded insights into the potential 
usefulness of these viruses as vaccine vectors. It is important to remark here that most 
of these studies have been carried out in the context of generating HIV immunity. 
Clearly, the correlates of HIV protection are deeply complicated by numerous viral 
(e.g. diversity and evasion strategies) and host (e.g. HLA haplotype and restriction 
factor expression) factors. While the primary goal of rAdV vaccines for HIV is to 
generate HIV-specific CTL responses, it is still largely unknown whether this is an 
effective correlate of viral protection or control. For these reasons, the discussion here 
will not focus on the controversial failures or successes of these studies, but rather on 
what these studies illustrate about inducing adaptive immune responses by rAdV 
vectors. The setbacks in using rAdVs for HIV should not necessarily act as a deterrent 
in using rAdV based vectors for HIV or other diseases. This is mainly because the 
failure of rAdVs in this setting may mostly reflect the general difficulty of eliciting 
responses that translate into protective immunity against HIV-1 (i.e. targeting 
conserved epitopes). Moreover, rAdV immunization safely induced insert-specific 
CD8+ T-cell responses in the majority of human vaccine recipients (231), which is an 
important minimum – though difficult to achieve – requirement of any potential 
vaccine. It was also recently shown that rAdV immunization can induce protective 
neutralizing anti-influenza hemagglutinin Abs when given as a boost to a DNA plasmid 
prime (234). 
 
5.6.2 Lessons from iterative trials 
Effective rAdV induced cellular immunity (CD8+ T-cell mediated) has been 
demonstrated in the literature. rAdV-5 vectors encoding immuno-dominant HIV 
proteins effectively controlled simian–human immunodeficiency virus (SHIV) 
infection in NHPs (235). Similarly, effective anti-Ebola virus immunity was also 
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generated with rAdV-5 vectors encoding immuno-dominant Ebola glycoprotein (236, 
237). However, in subsequent pre-clinical trials using a more difficult to control simian 
immunodeficiency virus (SIV) challenge model, the anti-SIV immunity generated by 
rAdV immunization was substantially less effective (238). Other vectors, namely 
rAdV-26 and rAdV-35, have also been shown to provide partial and complete 
protection, respectively, against Ebola challenge (239). rAdV-26 priming of rAdV-5 
immunization also seemed to enhance the induction of anti-SIV immunity (240). 
However, a general criticism of these SIV protection studies is that the challenge virus 
was not stringently heterologous to the virus genes used in the rAdV vaccine. Whether 
this is informative for rAdV immunization or SIV pathogenesis is not clear. 
  
A recent phase III trial (Merck-STEP) demonstrated that rAdV-5 did not induce 
efficacious anti-HIV-immunity (241), although this study has offered insights into 
potential advantages and disadvantages of using rAdVs as vaccine vectors. It is poorly 
understood whether this lack of efficacy was due to insufficient quality of the immune 
response towards diverse circulating virus or other complex virus and host factors. One 
explanation may have to do with the central memory CD8+ T-cell responses induced 
by rAdV-5, since replicating CMV vector-induced effector memory CD8+ T cells have 
been shown to be powerfully protective against heterologous SIV challenge (242, 243). 
A surprising finding of the STEP trial was that the rAdV-5 vaccinated group appeared 
to have an increased acquisition rate compared to the unvaccinated group, although 
acquisition was likely confounded by factors such as circumcision, seropositive HSV-2 
status, and AdV-specific Ab titers. There have been a few hypotheses put forth to 
explain these results. First, AdV vectors may have induced HIV-1 specific memory 
CD4+ T cells that were preferentially infected by HIV-1 (244, 245), although this is 
difficult to test directly in vivo. The induction of these T cells remains a potential issue 
with any HIV vaccine since the virus is CD4-tropic. In analyzing samples taken from 
human vaccinees, immunization with rAdV-5 vectors did not lead to anti-AdV-5 
cellular immunity that correlated with pre-existing Ab titers (246, 247). This was 
confirmed using cells from a different clinical trial employing rAdV-5 vectors (248). 
These studies suggest that rAdV does not induce HIV-susceptible activated T cells. 
Another hypothesis is that complexes of AdV-5 with Abs facilitate the activation of 
AdV-5 specific memory T cells (249), with the implication that the vaccine increases 
HIV acquisition because there are more activated target cells present for HIV to infect. 
Alternatively, rAdV was shown to preferentially induce AdV-specific memory CD4+ T 
cells expressing CCR9 and αV/β7 integrins in T cells in vitro from AdV seropositive 
individuals compared to seronegative individuals (244). The memory T cells here were 
also more susceptible to HIV infection in vitro. The mucosal homing phenotype may 
also suggest that these AdV-specific T cells could then facilitate dissemination of HIV-
1 in the gut. These analyses were however limited to T cells collected from blood, so 
the phenotype and antigen specificity of gut-resident lymphocytes, where much of the 
HIV pathogenesis occurs, may be different. Nonetheless, such studies are important to 
carry out so that the potential of viral vectors to cause increased acquisition of the target 
pathogen is not repeated. It will also be important to further investigate alternative AdV 
species, which are often even less well characterized compared to rAdV-5 in terms of 
their specific receptor usage and ability to transduce different cells. 
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Several limitations of rAdVs have been reported with the primary being a potential for 
high prevalence of pre-existing neutralizing Ab immunity, notably to AdV-5 (250). 
Since these Abs were found to attenuate immunogenicity of AdV-5 in mice, vectors 
derived from alternative AdV types with lower sero-prevalence or that were not 
attenuated by pre-existing AdV-5 immunity have been tested (251, 252). Of those, it 
was found that AdV-35 based vectors were the most efficient at circumventing pre-
existing immunity (251, 253). However, the role of natural infection induced Abs – or 
even rAdV immunization induced Abs – in blunting AdV vector immunogenicity 
remains controversial because it is unclear how well the Ab titers in these mouse 
experiments correlate with circulating titers found in the population. Mice might be 
poor indicators of AdV vector immunogenicity in humans since mice are an unnatural 
host for human derived AdVs. As an example, vectors based on rAdV-35 have shown 
weaker immunogenicity than rAdV-5 vectors in NHPs (227, 254, 255). More recent 
data from mice also demonstrate that vectors based on rAdV-35 and rAdV-26 are 
measurably less immunogenic than rAdV-5 based vectors (256). These authors also 
showed that AdV-26 has a higher sero-prevalence than previously realized, which 
suggests that current data on AdV seroprevalence may need to be reevaluated. Data 
from ongoing rAdV-35 trials may indicate useful NHPs are for predicting 
immunogenicity in humans (225). A phase 1 trial using rAdV-35 to vaccinate against 
TB recently reported that a single administration of rAdV-35 induced detectable CD4+ 
and CD8+ TB-specific T-cell responses, a homologous rAdV-35 prime-boost regimen 
induced lower cellular responses and had no detectable boosting effect (230). While 
anti-AdV-35 Abs from the prime immunization may be attenuating the boost, it may 
also be plausible that AdV-35 vectors are immunosuppressive (72). There may be other 
methods to circumvent pre-existing immunity. For flu, aerosol delivery of AdV 
particles to the lungs of NHPs generated effective flu-specific immune responses in the 
presence of pre-existing anti-AdV immunity (257). Future studies should continue to 
study these limitations and develop means to overcome them. 
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6 MATERIALS AND METHODS 
6.1 ISOLATION OF HUMAN PRIMARY CELLS 
6.1.1 Isolation of primary human DCs 
The experiments performed in this thesis and the accompanying papers were approved 
by the ethical review boards at Karolinska Institutet and US National Institutes of 
Health. We and others have developed methods to sort significant numbers of highly 
pure immature human DCs from blood (44-46, 54, 72, 180). pDCs and mDCs were 
sequentially separated based on differential expression of the BDCA markers, with 
mDCs having CD1c (BDCA-1) and pDCs having CD304 (BDCA-4) (34, 35). First, 
DCs and monocytes were enriched from total PBMC by either (i) aphaeresis of donor 
leukocytes and counterflow centrifugation elutriation to separate monocytes and 
lymphocytes based on cell size and sedimentation density (45), or (ii) by treatment with 
RosetteSep CD14+ enrichment kit (258). Such methods resulted in a fraction of cells 
highly enriched for monocytes and DCs. pDCs were then positively selected by 
staining with anti-CD304 monoclonal antibodies (mAb) directly conjugated to 
magnetic microbeads (Miltenyi). B cells expressing CD1c were depleted by staining 
with anti-CD19 mAbs microbeads (Miltenyi). mDCs were thereafter positively selected 
with mAbs against CD1c. Cell separation based on magnetic microbead conjugated 
mAb was performed on an AutoMacs instrument. Sequential magnetic sorting resulted 
in highly pure and phenotypically immature CD123 expressing CD304+ pDCs and 
CD11c expressing CD1c+ mDCs. These phenotypes were consistent with the 
established literature (37). pDCs and mDCs were then cultured in complete media 
(RPMI; 10% fetal calf serum; penicillin and streptomycin) supplemented with IL-3 and 
GM-CSF, respectively. Although pDCs may be isolated with anti-CD303 mAb, 
ligation of this receptor may ablate IFN-I production (259), phenotypic maturation, and 
optimal antigen presentation (260). 
 
6.1.2 In vitro differentiation of DCs (MDDC) 
The rarity of DCs in human blood and other tissues make the isolation of significant 
numbers of DCs challenging and thus present a significant roadblock in DC research. 
As such, primary monocytes may be differentiated into DCs in vitro (60). Highly pure 
monocytes (>90% CD14+) were obtained either by collection of plastic-adherent cells 
or by treating PBMCs with RosetteSep CD14+ enrichment kit (Stem Cell 
Technologies) (180, 258). Isolated monocytes were then subsequently cultured for 6 
days in complete media supplemented with suitable concentrations of recombinant 
human IL-4 and GM-CSF. 
 
6.1.3 Isolation of cutaneous DCs 
For paper II we used methods developed by Bond et al. to isolate cutaneous DCs 
subsets from healthy skin tissue obtained after reconstructive plastic surgery (64). A 
skin graft mesher (Zimmer) was used to mechanically expand skin in a net-like fashion 
in order to increase the activity of dispase, an enzyme that separates the dermal and 
epidermal layers. The layers were then pulled apart with forceps and incubated with 
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collagenase, which enzymatically disrupts the collagen fibers and the integrity of the 
tissue. After filtering through 75 µM pores, single cell suspensions were enriched of 
dDCs and LCs from the dermis and epidermis, respectively. Alternatively, the 
separated layers were incubated with collagenase and GM-CSF, which induced the 
cells to migrate from the tissue into the media. While these suspensions typically 
consisted of a higher percentage of DCs, the DCs present normally displayed a more 
mature phenotype compared to DCs isolated with collagenase alone. 
 
6.1.4 Isolation of total and naive human T cells 
In paper I, CD4+ and CD8+ T cells were isolated by depletion of CD19+ B cells and 
CD56+ NK cells from donor elutriation fractions enriched for lymphocytes (44). 
Lymphocytes were stained with anti-CD19 and anti-CD56 mAb conjugated to 
magnetic microbeads and depleted on AutoMacs columns (Miltenyi). An extensive 
flow cytometry panel was used to exclude dead cells and CD14+ and CD19+ cells from 
analysis of antigen specific memory T-cell responses. In papers III-IV we developed 
an alternative method to isolate CD4+ and CD8+ T cells from PBMCs (72). Buffy 
coats were treated with RosetteSep CD4+ or CD8+ T-cell enrichment kits (StemCell 
Technologies) and separated on density gradient centrifugation (Ficoll Paque, GE). The 
resulting cell fractions were at least 90 % CD3+ and CD4+ or CD8+ as determined by 
flow cytometry. These fractions contained a mixed population of naive and memory T 
cells, based on differential expression of CD45RA. The main contaminating population 
was CD19+ and each T-cell sort contained either CD4+ or CD8+ subsets. To sort the 
naive subset, total CD4+ or CD8+ T cells were treated with anti-CD45RO mAb 
conjugated to magnetic microbeads. The labeled cells were sensitively depleted on 
AutoMacs columns to yield populations of naive T cells that were at least 90 % CD3+, 
CD4+ or CD8+, CD45RA+, and CCR7+. This phenotype fits the standard definition of 
naive T cells. These cells were also shown to make mostly IL-2 (not IFNγ) and have a 
high capacity to proliferate upon stimulation, which are functions consistent with naive 
CD4+ T cells. The purity of all isolations was determined by flow cytometry before 
proceeding with subsequent experiments. 
 
6.2 ADENOVIRUS SUSCEPTIBILITY AND ACTIVATION OF DCS 
In this thesis we used methods to monitor rAdV infection of human DCs in vitro. rAdV 
vectors with genomic backbones encoding GFP transgenes under control of a CMV 
promoter and polyadenylation signals were used in these assays. First, freshly isolated 
and immature DCs in complete media were exposed to rAdV-5-GFP or rAdV-35-GFP. 
After 24 h incubation GFP expression was measured by flow cytometry. Although GFP 
expression was highest at 24 h in susceptible cells, GFP was also readily detectable 
after 8 h. We also assessed GFP in rAdV exposed PBMCs in a similar manner. Co-
staining for various surface markers allowed for the detection of GFP in different cell 
types with the PBMCs fraction. DC activation (or phenotypic maturation) was also 
measured after stimulation. Following exposure to rAdV-GFP or TLR-ligands, DCs 
were stained with mAbs against anti-CD80, CD83, CD86, CD40, or HLA-DR. 
Expression was then measured by flow cytometry. 
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6.3 EX VIVO ACTIVATION OF HUMAN T CELLS 
In papers I, III, and IV several methods were used to stimulate primary human T 
cells. In paper I, we activated CD4+ and CD8+ T cells specific to the cytomegalovirus 
pp65 antigen and measured recall responses to antigen. The responses were measured 
by intracellular staining for three cytokines (IL-2, IFNγ, TNF), a chemokine (Mip-1β), 
and a marker of degranulation (CD107a). Expression was detected by flow cytometry. 
Analysis of these five functions represents the majority of CMV specific T cells in the 
blood specific to pp65. To stimulate the recall responses to pp65 antigen, T cells were 
treated by either of two different, but complementary, methods: (i) with overlapping 
pp65 peptide pools that were compatible with both MHC-I and MHC-II and could thus 
activate CD8+ and CD4+ T cells, or (ii) with autologous DCs that had been infected 
with rAdV encoding for pp65 for 24 h previously (Figure 4; page 33). Both type 5 and 
35 rAdV encoding pp65 or empty, which acted as a control, were used. Both methods 
of activation were able to effectively activate memory T-cell responses in vitro. SEB 
was used as a control to show whether the intracellular straining worked correctly. 
 
In papers III and IV, we used three additional methods to activate sorted human T 
cells: (i) allogeneic DCs (Figure 5; page 34), (ii) plate immobilized anti-CD3 and anti-
CD28 mAb (Figure 6; page 35), or (iii) PMA and ionomycin. These conditions were 
shown to activate sorted total, memory, and naive subsets of both CD4+ and CD8+ T 
cells, where activation was assessed by measuring proliferation, cytokine (IL-2, IFNγ, 
TNF) and chemokine (Mip-1β) production, and nuclear translocation of NF-
κB/degradation of IκBα. Since methods (i) and (ii) activate T cells in a TCR dependent 
manner, we alternatively stimulated T cells with PMA and ionomycin, which activated 
T cells downstream of the TCR. The allogeneic reaction exploits the inherent cross-
reactivity of CD4+ T-cell expressed α/β-T-cell receptors (TCR) for peptide-bound 
MHC-IIs expressed on allogeneic DCs (261). Proliferation was measured by CFSE 
dilution or 3H-thymidine incorporation. Flow cytometry was used to measure cytokine 
levels, while the activation of NF-κB pathways was measured by Western blot. In these 
experiments, the nuclear and cytoplasmic contents were fractionated after stimulation 
by treatment with nuclear and cytoplasmic extraction kit NE-PER (Pierce). 
 
6.4 FLOW CYTOMETRY 
In papers I-IV flow cytometry was used extensively use to assess multiple functions of 
primary human DCs and T cells including, surface phenotype, DC maturation, T-cell 
activation, and the intracellular accumulation normally secreted proteins. In all 
experiments using flow cytometry, cells were stained with mAb directly conjugated to 
fluorescent dyes (e.g. FITC, PE, PerCP, APC, Alexa647, etc.) in 5 ml polystyrene 
round bottom tubes (Becton Dickinson). To measure surface expression of proteins, 
cells were washed in PBS-, centrifuged, blotted, and stained with mAbs. After 20 min 
incubate at 4 °C, cells were washed again in PBS- and immediately run on the flow 
cytometer. In the instance that the cells could not be run immediately, cells were fixed 
with 0.5 % paraformaldehyde and stored at 4 °C. Flow cytometry was also used to 
detect intracellular GFP expression. 
 
We also used flow cytometry to detect apoptotic, necrotic, or dead cells for two 
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particular reasons: (i) exclusion of these cells from the analysis, and (ii) measurement 
of viability. Dead cells were excluded from analysis by staining with either 7-AAD 
(eBioscience) or LIVE/DEAD fixable dead cell stains (Invitrogen), the latter of which 
was compatible with fixation and permeabilization procedures discussed below and 
described in (262). In papers III and IV we measured 7-AAD in combination with 
Annexin-V in order to measure T-cell viability (or survival) over a time-course of 
stimulation with different CD46 ligands. Co-staining with 7-AAD and Annexin-V 
enabled us to distinguish between necrotic/late apoptotic cells (7-AAD+/Annexin-V+), 
early apoptotic cells (7-AAD-/Annexin-V+), and live cells (7-AAD-/Annexin-V-). 
Prior to cell permeabilization when measuring intracellular cytokine we used green or 
violet LIVE/DEAD fixable dead cell dyes that bind amine groups. Due to the greater 
concentration of protein within cells compared to the plasma membrane, dead cells 
with porous plasma membranes display a greater fluorescence than live cells. 
 
In paper I we used previously developed methods to simultaneously measure 
intracellular accumulation of three cytokines (IL-2, IFNγ, TNF), a chemokine (Mip-
1β), and a marker of degranulation (CD107a) by flow cytometry (262-265). Protein 
accumulation was caused by treatment of cells during the stimulation time with two 
pharmacological compounds that inhibit protein secretory pathways: Brefeldin A and 
monensin. Briefly, following stimulation of T cells (with exogenous peptide or rAdV-
exposed autologous DCs) T cells were washed with PBS and stained with mAb against 
surface antigen. The mAb specific for CD107a was present during the course of the 
stimulation (6 h). After the surface staining, cells were treated with the 
cytofix/cytoperm kit (Becton Dickinson) and subsequently stained with mAb for the 
intracellular proteins. mAb were incubated for 20 min at room temperature in all these 
experiments. Before collecting cells on the flow cytometer, cells were washed one final 
time with cytofix/cytoperm wash buffer and fixed with 1 % paraformaldehyde. In 
papers III and IV, we used similar methods to detect intracellular IL-2, TNF, IFNγ, 
and Mip-1β following anti-CD3 and anti-CD28 or PMA/ionomycin stimulation.  
 
For paper I, we modified the above methods for intracellular cytokine staining in T 
cells in order to be able to measure IFNα production by pDCs (266). Following 
stimulation with TLR-ligands (CpG for TLR9, a TLR7/8-ligand) or rAdVs, pDCs were 
treated with the cytofix/cytoperm kit (Becton Dickinson) and subsequently stained with 
a mAb against multiple subtypes of IFNα (PBL/Interferon Source). This mAb was 
commercially available directly conjugated to FITC meaning that we could not use it in 
combination with GFP. However, we subsequently conjugated the mAb to Alexa647 
allowing for the simultaneous detection of GFP and IFNα in pDCs (59). ELISA was 
used to confirm flow cytometry data for IFNα. 
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7 RESULTS AND DISCUSSION 
At the onset of this thesis, there were both well and poorly understood aspects of how 
rAdV vectors interacted with primary human DCs and T cells. With the wide use of 
these vectors in clinical vaccine trials for a host of human pathogens (14, 17), we 
recognized a need to more thoroughly understand these interaction. Since that time, we 
and others have provided several unique insights into how rAdV vectors gain entry into 
DCs and how DCs may then respond to rAdVs. rAdV vectors may also affect T-cell 
activation in both DC-independent and dependent ways. In this section, we will 
summarize and discuss the results presented in papers I-IV. 
 
7.1 ADENOVIRUS INFECTION AND RECEPTOR USAGE IN DCS 
As discussed in the introduction, DCs are potent professional antigen presenting cells 
(pAPC) that possess a unique ability to prime adaptive immune responses (33, 35). 
After rAdV immunization, DCs are likely to detect rAdV vectors in the periphery and 
may therefore play a significant role in regulating immunity towards the vector itself 
and/or encoded transgenes. In paper I, we first addressed the susceptibility of primary 
immature mDCs and pDCs, freshly isolated from human blood, to two different rAdV 
types: species C AdV-5 and species B AdV-35. The DCs were exposed to rAdV 
vectors encoding a GFP transgene for 24 h at which time the frequency of GFP+ cells 
was measured by flow cytometry. It was found that rAdV-35 infected both mDCs and 
pDCs about ten times more efficiently than rAdV-5. Moreover, mDCs were 
consistently more susceptible than donor-matched pDCs. Infection of pDCs by rAdV-5 
was nearly undetectable except at very high viral doses. These finding in mDCs and 
pDCs confirmed earlier reports in other DC types (255, 267). Following rAdV-5 
immunization in mice mDCs were found to be more susceptible to infection than pDCs 
(210). Skin DCs were also found to be more efficiently infected by rAdV-35 than 
rAdV-5 (268). rAdVs pseudotyped with species B fibers to mediate CD46 binding 
infected PBMCs more efficiently as well (269). We found a similar pattern of 
susceptibility in papers II and III using MDDCs. Although no donor-matched 
experiments were performed, we found that mDCs were more susceptible to rAdV 
infection than MDDCs. Data in paper II and presented in (59) show that cutaneous 
DCs (LCs and dDCs) are also susceptible to both rAdV-5 and rAdV-35 infection. 
Others have also found that cutaneous DCs are susceptible to rAdV infection (178). 
Recently, it was shown that murine CD11c+ DCs become infected with rAdV-5 in vivo 
and are necessary to generate CD8+ T cell responses against rAdV encoded genes 
(210). This study demonstrates a significant role for rAdV-5 infected DCs in mediating 
immunogenicity, although it remains plausible that DC acquisition and presentation of 
AdV-encoded proteins from infected non-hematopoietic cells (e.g. fibroblasts) may 
also be necessary for generating immunity. Future studies should examine the in vivo 
contributions of direct-presentation and cross-presentation in generating CD4+ and 
CD8+ T-cell responses to rAdV-encoded antigens. In light of the reports in the 
literature on the topic of vaccine targeting to DCs, it is important to clarify here that our 
studies have not directly addressed whether efficient rAdV infection of DCs is 
beneficial or not for generating vaccine induced T-cell responses. However, 
susceptibility of DCs to AdV may still influence innate recognition and responses.  
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We continued in paper I by assessing receptor usage of these two rAdV vectors on 
human DCs. As described above, rAdV-35 uses the complement regulatory protein 
CD46 as its primary attachment receptor on a host of human cell types (157, 164, 165). 
The trimeric fiber knob protein mediates high affinity and avidity binding of rAdV-35 
to a region within the extracellular SCR1 and 2 domains of (164, 166, 270-272). In 
contrast, the receptor usage of AdV-5 is less well defined. CAR is the described 
primary receptor for rAdV-5 on epithelial cells (169-172). However, AdV-5 may infect 
cells independent of CAR (44, 173, 175-179, 273). As such, we began by measuring 
surface CD46 and CAR expression on immune cells in human peripheral blood. We 
found that mDCs and pDCs, in addition to T cells, B cells, and monocytes, expressed 
high levels of surface CD46. In contrast, CAR expression was undetectable by flow 
cytometry. To test whether AdV-35 required CD46 binding to infect DCs, we treated 
DCs with rAdV-35 or rAdV-5 encoding GFP in the presence or absence of two mAbs: 
clone 13/42 bound within the SCR1 domain and clone M177 bound within the SCR2 
domain (270, 274) (Figure 1). We found that both mAbs significantly blocked rAdV-
35, but not rAdV-5, infection of mDCs and pDCs. In contrast, the one available anti-
CAR mAb that has been described to block rAdV-5 binding (275) had no effect on 
either rAdV-5 or rAdV-35 infection. We subsequently performed these experiments in 
CAR expressing cells lines and found a similar effect (W.C. Adams, unpublished data). 
In paper IV we also showed that trimeric rAdV-35 knob proteins were efficient at 
blocking rAdV-35 infection of MDDCs, supporting the fact that the knob region of the 
capsid is required for infection. Taken together, these data indicate that rAdV-35 
infection of mDCs and pDCs is dependent on knob-CD46 interactions whereas the 
receptor for rAdV-5 was less clear, but seemed to be independent of CAR binding. In 
paper II, rAdV-5 was found to infect CAR-expressing cutaneous DCs in a partially 
CAR-dependent manner. The expression of CAR on tissue resident DCs may not be 
surprising since gut resident DCs also express an extensive repertoire of other tight 
junction proteins (276). We then followed-up on the finding that a majority of rAdV-5 
infection in human primary DCs occurred independent of CAR. A report showing that 
the iron-binding protein lactoferrin (Lf) facilitated epithelial cell infection by species C 
AdV (173) prompted us to test this receptor use in DCs. Lf is a highly relevant protein 
since Lf exists at mucosal tissues and in many body fluids (milk, tear fluid, saliva, nasal 
secretions and vaginal mucus, and serum), which makes it plausible that rAdV-5 
contacts Lf in the periphery (277, 278). Lf concentrations increase during the acute 
phase of many infections. Lf also directly simulates DCs and modulates their 
migration, cell activation and induction of T-cell responses (279-281). In support of the 
findings reported by Johansson et al. (173), we reported in paper II that Lf strongly 
enhanced rAdV-5 infection of all tested blood and skin DC subsets (180). A related 
iron-binding protein, Transferrin (Tf), did not cause a similar effect. DC activation by 
Lf was also not the cause of increased infectivity in our experiments. While others have 
found that Lf inhibits infection of HIV-1 (282), Semliki Forest virus (SFV) (283), 
human Papillomavirus (284) and AdV-2 (285, 286), we found no evidence that Lf 
negatively affected rAdV-5 infection of human DCs (287). We did however observe 
that Lf blocked SFV infection of DCs (W.C. Adams, unpublished data). The receptor 
for human Lf remains unclear on DCs or other cell types (288, 289). In paper II we 
additionally compared Lf of human and bovine origin. While Lf from these species 
have similar AA sequences and tertiary protein structures (290), BLf has four sites for 
potential N-linked glycosylation, of which two or three are occupied by high-mannose-
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type oligosaccharides and natural HLf has two N-acetyl-lactosaminic-type 
oligosaccharides (291-293). In comparing Lf from these species we observed that 
bovine Lf had a significantly greater effect than human Lf on rAdV-5 infection. The 
positive effect of bovine Lf on rAdV-5 infection was ablated on MDDCs in the 
presence of mannan or anti-DC-SIGN mAb or when the Lf was treated with the 
enzyme EndoH to remove N-linked glycans. From these data we suggested that bovine 
Lf might be a useful tool for increasing rAdV-5 transduction in vitro or in vivo. Also, it 
is plausible that there are numerous Lf species expressing different sugar moieties that 
may interact with other carbohydrate receptors to facilitate AdV infection of DCs. 
 
7.2 PHENOTYPIC MATURATION OF DCS BY ADENOVIRUS 
As discussed in the introduction to this thesis, DCs have the capacity to undergo 
phenotypic maturation upon recognition of foreign antigen or nucleic acid. Thus, in 
papers I and III we evaluated the ability of rAdV-5 and rAdV-35 to activate human 
mDCs and pDCs. For these experiments freshly isolated and phenotypically immature 
DCs were exposed to a range of doses of rAdV-5 or rAdV-35 for 24 hours. Flow 
cytometry was then used to measure surface expression of panel of markers of 
maturation: CD80, CD83, CD86, CD40, and HLA-DR. Even at lower virus doses (10 
ip/cell) rAdV-35 was found to mature mDCs, pDCs, and MDDCs to a degree that was 
equal to positive controls like LPS, CpG, or a TLR7/8-ligand. While others have found 
AdV-5 can mature DCs (294-297), there may be substantial differences in the source of 
DCs and viral doses between studies. Receptor usage may be linked to the capacity of 
different rAdV types to induce maturation. Although the mechanisms of cellular entry 
may differ between AdV species and cell type (14), it is likely that viral nucleic acids 
could signal through endosomal or cytosolic expressed PRRs and thereby initiate DC 
maturation. One potential explanation for why or how certain AdV species induce 
maturation while others do not may be that species C and B AdVs have different 
kinetics of endosomal retention and escape to the cytosol following receptor mediated 
endocytosis (298). PRR recognition in these compartments may thus be affected by 
intracellular trafficking kinetics of different AdVs. In vivo, maturation of mDCs 
induced by rAdV vectors was dependent on IFN-I signaling (211), indicating that 
phenotypic maturation of DCs may be induced directly through infection or facilitated 
indirectly through cytokine production. What PRRs are responsible for rAdV mediated 
DC maturation remains largely unknown. 
 
7.3 ADENOVIRUS INDUCTION OF IFNα  
A second crucial function of DCs is their ability to produce cytokines that orchestrate 
innate and adaptive immune responses. As mentioned in the introduction, pDCs 
produce IFN-I in response to infection by DNA viruses (31). Thus, we hypothesized 
that rAdVs may induce IFN-I and that this induction may occur through TLR9 
expressed in pDCs. To address our hypothesis, we exposed pDCs to rAdV-5 or rAdV-
35 for 2 to 24 hours. IFNα was measured in the supernatants by ELISA or Brefeldin A 
was added to the cultures to allow for intracellular accumulation of the cytokine. These 
cells were then fixed and permeabilized and stained for intracellular IFNα. In both 
assays rAdV-35, but not rAdV-5, was a potent inducer of IFNα in pDCs. We measured 
production of this cytokine at levels nearly comparable to the positive controls, CpG C 
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and TLR7/8-ligand. IFNα was found at detectable but very low levels in mDC cultures 
treated with rAdVs, although it could not be ruled out that this IFNα was from the few 
contaminating pDCs. Concurrently with our study, other groups found that IFN-I 
induction in PBMCs was shown to be a feature unique to CD46-using AdVs (202, 
203). IFNα/β production was dependent on endosomal TLR9 signaling, as it was 
blocked by inhibitors of endosomal acidification (e.g chloroquine). Yet, based on the 
current model whereby the AdV nucleic acids remains contained within the capsid 
structure while trafficking to the nuclear membrane, it is difficult to understand how 
pDCs could sense protected nucleic acids. One explanation may be that intracellular 
viral trafficking is stochastic. That is, some AdV particles disintegrate before reaching 
the nuclear membrane and expose their nucleic acids that can activate PRRs, while 
others complete their trafficking to the nucleus and undergo replication. As discussed in 
the introduction, there may be additional sources of systemic IFNα/β, especially for 
non-CD46-using AdVs. Finally, it will be interesting to further study how CD46 
engagement may affect production of other cytokines. We are currently studying 
whether AdVs can modulate DC function because others have reported that CD46 
engagement by MV (125) and CD46-using AdVs (299) blocks IL-12 production in 
myeloid lineage APCs. Our preliminary results with CD46-ligation substantiate these 
reports, however we have observed that AdV-35 infection enhances LPS-induced IL-12 
in a synergistic manner (W.C. Adams, unpublished data).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Requirement of CD46 to induce IFNα in pDCs. Freshly isolated pDCs were 
exposed CpG C, rAdV-35, rAdV-5.35Fiber, and rAdV-5 for 18 hours. IFNα was 
measured in the supernatants by ELISA. 
 
Related to the induction of IFNα we had a lingering question: Would rAdV-5 induce 
IFNα in pDCs if it was modified to use CD46 for entry? The corollary of this question 
being, does IFNα induction require a chemical signature present specifically in the 
nucleic acid content of rAdV-35? To attempt to answer these questions we exposed 
freshly isolated pDCs to CpG C, rAdV-5, rAdV-35, or rAdV-5 with fibers from rAdV-
35 (rAdV-5-35Fiber) encoding GFP and measured infection and IFNα in the 
supernatants by ELISA. First, we found that the 35-fiber enabled rAdV-5 to infect 
pDCs like rAdV-35, whereas the wild-type rAdV-5 was not able to infect pDCs as we 
have shown before (data not shown). Interestingly, addition of the 35-fiber enabled 
rAdV-5 to induce IFNα like rAdV-35, even though wild-type rAdV-5 could not 
(Figure 3). These data show that entry pathways associated with CD46 mediate IFNα 
production and that rAdV-5 probably does not induce IFNα because it does not infect 
pDCs, but not because its genome cannot replicate or activate PRRs in pDCs. Also, 
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CD46 engagement alone is not sufficient to induce detectable cytokine production 
(W.C. Adams, unpublished data). 
 
 
7.4 DC PRESENTATION OF RECOMBINANT ADENOVIRUS-ENCODED 
ANTIGEN TO T CELLS 
Due to inherent differences between rAdV-5 and rAdV-35 in their capacity to infect, 
mature, and induce cytokine production in human primary DCs, we next assessed 
whether these vectors might differentially affect T-cell activation. In paper I to address 
this question we setup an autologous DC-T-cell co-culture system to measure CMV 
recall responses. As explained in the material and methods section of this thesis and 
outlined in Figure 4, mDCs or pDCs were exposed to rAdV vectors encoding the 
immune-dominant pp65 gene of CMV. After 24 hours, the infected cells were washed 
and transferred at a 1:10 ratio to sorted autologous CD4+ and CD8+ T cells from 
donors with detectable CMV responses. The rAdV-infected DCs were compared to 
overlapping pp65 peptide mixes, which were used as the positive control. After 6 hours 
of co-culture T cells were analyzed for intracellular expression of three cytokines (IL-2, 
IFNγ, TNF), a chemokine (Mip-1β), and a marker of degranulation (CD107a). 
Expression of one or several of these 5 functions represents the majority of the antigen 
specific memory T-cell response against latent CMV infection in healthy donors.  
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic of autologous DC:T-cell co-culture. 
 
We found that rAdV-pp65 exposed DCs activated a frequency of memory CD4+ and 
CD8+ T cells comparably to the overlapping peptide mix. rAdV-35 exposed DCs were 
more efficient than rAdV-5 and mDCs were more potent than pDCs. Taken together, 
these data suggest that rAdV-infected DCs retained a potent capacity to process and 
present antigen to activate T cells. While infected DCs likely displayed rAdV-derived 
peptide on MHC-I to activate CD8 T cells, the mechanisms for MHC-II presentation to 
activate CD4+ T cells were less clear. Since we did not detect significant cell death or 
expect secretion of endogenously produced protein (i.e. pp65), it is plausible that some 
form of cross-presentation may explain how CD4+ T cells became activated. As such it 
may be interesting in the future to compare the BDCA-3+ mDCs subset in this system. 
 
7.5 REGULATION OF NAIVE T-CELL ACTIVATION BY ADENOVIRUS 
While these studies were instructive in demonstrating how efficient rAdV-infected 
primary DCs were at activating memory T cells, we were presented with another 
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question: do rAdV vectors affect the activation of naive T cells? We sought to address 
this question in paper III because it was potentially more relevant for understanding 
the immunogenicity of these vectors in a vaccination setting. Initially, we set up 
allogeneic DC:T-cell co-cultures (Figure 5). DCs were exposed to rAdV-5 or rAdV-35 
for 24 hours before being added at a 1:10 ratio to sorted naive CD4+ T cells. Another 
critical difference between these co-cultures and those used in paper I was that the 
DCs were not washed and thus free virus was available to affect T-cell activation.  
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic of allogeneic DC:T-cell co-culture. 
 
We observed inhibition of naive CD4+ T-cell proliferation when rAdV-35, but not 
rAdV-5, was present. This occurred even when the frequency of infected DCs was 
controlled for and was not due to downregulation of MHC-II or measurable DC death. 
In fact, we had already shown in paper I that rAdV infected DCs maintained pAPC 
function. While a report had shown that rAdV-5 negatively affected T-cell proliferation 
(300), we did not observe this in our experiments. One explanation for the differences 
in these findings may be that these authors used higher doses of rAdV than we have in 
our studies. MV, another CD46 using human pathogen, also inhibited allogeneic-DC 
induced proliferation of naive CD4+ T cells (301). These findings are consistent with 
the immunosuppressive properties of MV (302, 303). 
 
7.6 IMPACT OF CD46 ENGAGEMENT ON T-CELL ACTIVATION 
Based on our observations of selective inhibition of T-cell proliferation by rAdV-35 
and that supernatants from infected DCs were sufficient to inhibit proliferation, we 
hypothesized that rAdV-35 might be directly impacting naive CD4+ T-cell 
proliferation via binding its receptor CD46. We addressed this hypothesis primarily in 
paper III, and followed up on these studies in paper IV using alternative CD46 
ligands. First though we sought to establish whether rAdV-35 could bind CD46 on T 
cells. To do this we assessed the ability of rAdV-35 and the CD46 mAbs (clones 13/42 
and M177) to induce receptor downregulation, a feature of CD46 ligation. We found 
that rAdV-35 and CD46 mAbs caused receptor downregulation, which indirectly 
showed that binding with CD46 occurred. This finding has precedent in that other 
CD46-using pathogens cause a similar effect (111-118). As mentioned, a membrane 
trafficking motif within the CD46 cytoplasmic domain (121) facilitates induced CD46 
downregulation in lymphoid cells (120).  
 
The basis for our hypothesis that rAdV-35 may directly affect T-cell activation was 
discussed in the section on CD46 function. Briefly, we were intrigued by four reports 
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on CD46 in particular: (i) CD46 engagement had signaling capacity in monocytes that 
led to reduced IL-12 (125), (ii) CD46 was a regulator of naive CD4+ T-cell 
proliferation and cytokine production (109), (iii) CD46 drove CD4+ T cells towards an 
IL-10 producing regulatory phenotype (136), and (iv) CD46 engagement induced 
abortive proliferation of CD4+ T cells (132). In our studies we compared rAdV-35 to 
rAdV-5 and used two mAbs (previously discussed clones 13/42 and M177) to mimic 
rAdV-35 binding. We also used rAdV-35 mutant viruses with ablated CD46 binding. In 
these assays, sorted naive CD4+ T cells were stimulated with plate-immobilized anti-
CD3 and anti-CD28 mAbs (Figure 6). As noted in paper III, we selected to include 
CD28 co-stimulation for two reasons. First, naive T cells required this signal to become 
activated. And second, we had observed that rAdV-35 infection led to upregulated 
expression CD80 and CD86 on DCs, which are the natural ligands of CD28. This is an 
important distinction between our work and others, where CD28 co-stimulation was not 
included.  
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic of anti-CD3/CD28 mAb stimulation of naive CD4+ T cells. 
 
We found that CD46 ligation by either mAb (clones 13/42, but not M177) or whole 
rAdV-35 particles efficiently blocked proliferation of naive CD4+ T cells (72). As 
controls, rAdV-5 and mutant rAdV-35 vectors with ablated CD46 binding had no effect 
on T-cell proliferation. In paper IV, we followed up on these findings using a panel of 
recombinant trimeric rAdV-35 knob proteins that had increasing affinity for CD46 
(165). We used a wild-type knob (35K) that bound CD46 with a KD=14.64 nM, a 
higher affinity mutant (35K++), and a CD46-binding deficient mutant (35K279). The 
mutants were generated from an E. coli screening library. 35K++ contained two AA 
substitutions (Asp to Gly and Thr to Ala) at positions 207 and 245, respectively, and 
bound CD46 with 23.2-fold higher affinity (KD=0.63 nM). 35K279 was constructed 
with a single Arg to Cys substitution at position 279 that completely ablates CD46 
binding. The CD46 binding knob proteins induced downregulation of CD46 on T cells 
like rAdV-35 and anti-CD46 mAbs. In support of our previous findings (72), we found 
that CD46 engagement by 35K and 35K++ reduced proliferation in naive CD4+ T 
cells. However, plate immobilization of the knob proteins was required – potentially 
due to increased avidity for the receptor – since soluble proteins had no effect. The 
control 35K279 protein had no effect on proliferation, suggesting that non-specific 
steric hindrance caused by the presence of knob proteins was the cause of reduced 
activation. 
 
We observed differential effects of rAdV-35 on naive CD4+ and CD8+ T-cell 
proliferation in paper III. In the case of CD8+ T cells, we observed no effect with 
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rAdV-35. The clone 13/42 anti-CD46 mAb blocked proliferation in both T-cell subsets. 
However, the effects of clone 13/42 on CD8+ T cells varied noticeably between donors. 
We hypothesized that different thresholds of activation may be one explanation. To this 
end, we performed additional experiments in which the strength of CD3/CD28 
signaling was titrated (Figure 7). As CD3/CD28 signals increased, clone 13/42 still 
inhibited CD4+ T-cell proliferation whereas it had less of an effect on CD8+ T-cells.  
 
A           B 
 
 
 
 
 
 
 
 
         
 
 
Figure 7. Effect of anti-CD46 mAb clone 13/42 on naive (A) CD4+ and (B) CD8+ T-
cell proliferation induced by a range of anti-CD3/CD28 concentrations. Proliferation 
was measured on day 5 in triplicate by 3H-thymidine incorporation (mean ± SD). 
 
In papers III and IV, we next assessed the impact of CD46 ligation on early cytokine 
production. We analyzed three relevant cytokines (IL-2, TNF, IFNγ) and one 
chemokine (Mip-1β) made by CD4+ T cells upon CD3/CD28 activation. We chose to 
analyze IL-2 since it represents a major helper function of CD4+ T cells, is essential for 
T-cell growth (304), and has been shown to be modulated by CD46 (109). IFNγ 
production was also analyzed since it had been reported that CD46 ligation blocked 
IFNγ in CD8+ T cells (144). An important inflammatory cytokine, TNF, and a 
chemokine that recruits CD8+ T cells to DC:CD4+ T-cell conjugates in lymph nodes, 
Mip-1β (305) were also monitored. While the total CD4+ T-cell population made all 
four of these functions in response to CD3/CD28 stimulation, sorted naive CD4+ T 
cells made mainly IL-2, but only modest TNF and IFNγ, and undetectable levels of 
Mip-1β. rAdV-5 had no significant effect on cytokine production. Instead, CD46 
ligation – by either mAb or rAdV-35 – led to strongly reduced IL-2 and TNF, but had a 
more modest or no effect on IFNγ and Mip-1β. In paper IV, we confirmed these 
findings by showing that CD46 engagement with either the 35K or 35K++ trimeric 
knob proteins significantly blocked IL-2 production in sorted total and naive CD4+ T 
cells. As expected, the 35K279 mutant knob protein with deficient CD46 binding had 
no effect. Since the IL-2 gene is a major target of NF-κB transcription factor activity 
(129), in paper III we assessed NF-κB activation in total CD4+ T cells. Nuclear 
translocation of the p65 subunit and cytosolic degradation of its regulatory component 
IκBα were measured by western blot. CD46 ligation led to deficient nuclear 
translocation of p65 and IκBα was not degraded, which together indicate deficient 
activation of this transcription factor pathway. This may provide a general mechanism 
to explain the reduced proliferation and IL-2 in these cells. In regards to CD46 driving 
IL-10 production by Tr1 cells, we have not addressed that possibility for rAdV-35 for 
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two reason. First, IL-10 is induced by CD3/CD46 stimulation in the absence of CD28 
co-stimulation and the presence of exogenous IL-2. We argue that in viral infection 
CD28 signaling would likely be present and IL-2 is actually reduced in our hands. 
Second, we have found that IL-10 can be induced in CD4+ T cells with polyclonal CD3 
and CD28 stimulation (W.C. Adams, unpublished data). This IL-10 production is likely 
a result of polyclonal activation rather than activation or differentiation of certain T-cell 
subsets, so it is unclear to us whether CD46 ligation really induces T-cell differentiation 
as has been proposed. 
 
The potential implications of CD46 engagement by rAdV vectors are numerous. 
Firstly, CD46 downregulation has been shown to make cells more sensitive to 
autologous complement mediated lysis (119). Thus, T cells may be less protected from 
autologous complement killing after infection or vaccination with rAdV-35. This may 
negatively impact the activation of naive CD4+ T cells and thereby helper T-cell 
responses. Helper CD4+ T-cell responses are essential for optimal generation of 
cellular (CD8+ T cells) and humoral (B cells) memory (92, 94, 306-308). Proliferation 
and IL-2 production are both important functions of helper T cells, so it is plausible that 
blocking these functions would further curtail helper T-cell responses. We speculated in 
paper III that these apparent immune-suppressive effects of rAdV-35 may partially 
explain why these vectors are less immunogenic in non-human-primate preclinical 
trials (227, 254, 255). Homologous rAdV-35 prime-boost vaccination in humans also 
showed lower immunogenicity and no boosting compared a single immunization (230), 
although it was unclear from this study whether this result was due to AdV-35 Abs 
from the prime or some immunosuppressive effect of rAdV-35 vectors. The in vivo 
setting may be more complex than involving CD46 interactions alone. The extent to 
which this T-cell inhibition occurs in vivo is currently unknown, but our findings raise 
important questions about the spatio-temporal aspects governing CD46 modulation of 
T-cell activation. To this end, we have observed that no inhibition occurs with CD46 
mAbs if they are added 15 minutes prior to CD3/CD28 activation (W.C. Adams, 
unpublished data). AdVs were able to still block activation in this setting, but these 
observations should be further investigated. It is also currently unknown how or where 
rAdV vectors may contact DCs or T cells in vivo after infection or vaccination. 
Interaction with T cells in the periphery or lymph nodes, which would require 
trafficking through lymphatic vessels, are plausible scenarios. Intravital AdV-tracking 
studies may be useful to elucidate such questions. It must also be remembered that after 
infection or vaccination CD46 signals would originate from both natural complement 
activation (e.g. C3b) as well as from the CD46-using pathogen itself. To my 
knowledge, no studies have analyzed how these signals would interact with or 
counteract each other. Understanding the effects of these dual signals shall help 
elucidate the in vivo roles of CD46. 
 
Another further area of interest relating to the function of CD46 is the downstream 
signaling cascades. As discussed in the introduction, CD46 exists as four isoforms that 
express one of two cytoplasmic tails (cyt-1 and cyt-2) (126). Marie et al. first addressed 
these questions in transgenic mice expressing human CD46 and found profound 
differences between the signaling transmitted through these cytoplasmic tails (109). It 
has been suggested that cyt-1 expression promotes T-cell activation, but cyt-2 causes 
inhibition of T-cell activation (135). Our analysis of cyt-1 and cyt-2 mRNA revealed 
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that peripheral CD4+ T cells expressed an even ratio of these cytoplasmic tails (W.C. 
Adams, unpublished data). These findings raise tantalizing questions such as: (i) Is 
there competition between the cytoplasmic tails for kinases and adaptor molecules? (ii) 
Do the cytoplasmic tails compete with other co-stimulatory molecules and affect their 
function? (iii) Do the cytoplasmic tails play different roles at different time points of T-
cell activation? (iv) Does CD46 engagement cause physical or steric interference with 
formation of the immune synapse? (v) And do different CD46 ligands transmit 
different signals? Using siRNA (143, 309) it may be possible to knockdown different 
cytoplasmic domains in primary T cells as a way to being answering questions (i-iii). 
Our observation that CD3/CD28/CD46 treatment was equivalent in strength to CD3 
alone indirectly suggests that CD46 may be out-competing CD28 for signaling kinases 
or adaptor signaling molecules (W.C. Adams, unpublished data). Regarding question 
(iv), engagement of CD46 may misdirect formation of lipid rafts and microtubule 
organizing centers away from the immune synapse and toward the sites of CD46 (144, 
145). Binding of the large AdV particle might also interfere sterically with DC:T-cell 
contacts, although we find this possibility unlikely since we have seen similar 
inhibitory effects with the smaller mAbs and trimeric knob proteins. In relation to 
question (v), we have already observed that while SCR1 targeting mAbs block 
proliferation and IL-2, SCR2 targeting mAbs only block IL-2. These differences may 
be due to inherent properties of the mAb, but may also suggest that binding affinity and 
avidity may influence CD46 signaling activity. It will also be interesting in the future to 
study whether the natural ligand of CD46, C3b, recapitulates the effects of AdV-35 we 
have reported in our studies or if it has completely different effects. Since C3b binds 
between the SCR3 and 4 domains, the effects may indeed be very different with the 
natural ligand. Induction of autophagy by CD46 occurred specifically through the cyt-1 
domain (309). Since autophagy occurs constitutively in lymphoid cells, a possible 
induction of autophagy in T cells may also play a role in affecting T-cell function. 
Whether this occurs is unknown, but it would be important to analyze. In conclusion, 
further dissection of downstream CD46 signaling is required in order to more fully 
understand how CD46 imparts both negative and positive regulatory effects on T cells. 
 
In summary, the findings on the interactions of AdV-35 and CD46 illustrate how 
different vaccine components may affect naive CD4+ T-cell activation. This activation 
is both indirectly and directly related to the differentiation of effector and memory T-
cell fates, which will ultimately determine vaccine efficacy. More still needs to be 
learned about the ways that AdV-35 suppressed naive CD4+ T cells impact the quality 
of adaptive immune responses generated towards encoded antigens. 
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8 CONCLUSIONS 
At the onset of this thesis we aimed to study how rAdVs interact with human immune 
cells in order to better understand how these vectors may be inducing immune 
responses during vaccination. We realized an opportunity to study AdV in the context 
of human primary immune cells, as much of the published work used cell lines, in vitro 
differentiated DCs, or mice. As outlined in the introduction, there are numerous well 
defined differences between in vitro differentiated DCs and primary DCs. Furthermore, 
murine DC subsets differ to some degree and immunization studies in these animals 
may not accurately predict vaccine efficacy in vivo for human diseases like HIV-1. 
Ultimately, mice and humans diverged at least 65 million years ago, have vastly 
different body sizes and basal heart rates, and have evolved in separate ecological 
niches (310). A specific example is that mice do not seem to express a homologue of 
CD46, the receptor for AdV-35. In studying innate immune cell susceptibility to and 
recognition of AdVs we focused our efforts on primary human pDCs and mDCs. 
Because antigen presentation is a major function of these pAPCs, we became interested 
in how rAdVs influence DC-mediated activation of naive and memory T cells. As was 
discussed at length throughout the thesis, DCs and T cells play major roles in the 
generation of both innate and adaptive immune responses, respectively, after viral 
infection or vaccination. The work presented in this thesis provides evidence that 
substantiate the following four general conclusions: 
 
• rAdV-35 infects and matures human mDCs and pDCs more efficiently than 
rAdV-5 and also induces IFNα in pDCs. 
 
• rAdV-35 infection of mDCs and pDCs is dependent on CD46, whereas CAR is 
not implicated in rAdV-5 infection of these cells. Rather, lactoferrin enhances 
rAdV-5 infection in several human DC subsets. 
 
• rAdV-infected DCs can activate autologous transgene-specific polyfunctional 
memory T cells, indicating that infected DCs retain pAPC capacities. 
 
• rAdV-35 attenuates activation of naive CD4+ T cells via engagement of its 
receptor CD46. Reduced IL-2 and proliferation caused by rAdV-35 can be 
mimicked by anti-CD46 mAbs and trimeric AdV-35 knob proteins. 
 
  40 
9 FUTURE DIRECTIONS 
Current vaccines provide potent individual and herd protection against human 
pathogens. In fact, the vaccine for AdV represents a prime example. Oral AdV 
vaccination induces effective immunity against subsequent natural exposure to AdV-4 
and AdV-7 (311) and has been used extensively to significantly reduce acute 
respiratory disease-associated morbidity in US military recruits (312). This vaccine and 
the previously mentioned YFV vaccine induce potent and pathogen-specific adaptive 
immunity. Vaccines are effective prophylactic treatments on a herd basis also because 
they are cost-effective and minimally invasive. As such, vaccines continue to represent 
the optimal solution to confronting present and emerging human pathogens. The new 
era of vaccine development, where past empirical methods may not work for these 
pathogens, will require a vastly increased understanding of the human immune system. 
Continuing from this thesis, it may be of interest to further elucidate what role (if any) 
infection of DCs plays in the generation of cellular responses in vivo. For example, are 
naive T cells activated by direct or cross-presentation of rAdV derived antigen? We 
must also seek to understand the cellular and molecular determinants governing 
lymphocyte differentiation and fate (e.g. effector vs. memory T cells) after viral 
infection or vaccination. That is to ask: can vaccines be designed or tailored to induce 
immunological memory with the requisite specificity and potency to induce suitable 
correlates of protection? The specificity and potency relate to both effector cell function 
and neutralizing Ab responses. Viral vectors, despite significant setbacks, continue to 
represent a powerful and immunogenic pathogen-gene delivery vehicle. Whether viral 
vectors can induce the necessary immune specificity from encoded pathogen genes – 
after all, a DNA AdV is quite different from a RNA retrovirus – remains to be 
determined. As reported in thesis, receptor binding by a viral vector may dysregulate T-
cell response. Generating specific neutralizing Abs and protective T-cell responses 
depends not simply on gene delivery, but also – and potentially more so – on the 
complex activation of complement and the innate immune responses that shape the 
formation of adaptive immunity. That is, the quality of the memory response is 
paramount to the quantity in determining vaccine efficacy (313). Both basic research 
and iterative vaccination trials will be essential to answering these questions and 
designing vaccines against pathogens for which there is currently none (314). As 
demonstrated in this thesis and by many others before and concurrently, AdVs will 
nevertheless continue to be vital tools in helping to reveal mechanisms of immune 
system regulation and an instrumental part in understanding human immunology. 
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